var docs;if (!docs) docs =[]; docs["56"]={"5602":"<p><b>Title</b> Bromazepam / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromazepam. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Minimal increases in bromazepam systemic exposure are expected with concomitant use of a strong CYP3A4 inhibitor (e.g., itraconazole). No action needed.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole*, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In eight healthy subjects, concomitant administration of itraconazole (200 mg daily x 6 days) with bromazepam (3 mg single dose on day 4) increased bromazepam Cmax and AUC approximately 4.5% and 9% respectively, and nonsignficantly affected bromazepam pharmacodynamics (e.g., impaired psychomotor performance) when compared to bromazepam with placebo.<sup>1</sup> In twelve healthy subjects, nonsignificant bromazepam (3 mg single oral and rectal dose) pharmacokinetic and pharmacodynamic changes were observed following coadministration with fluconazole (100 mg QD), though the author suggests the fluconazole dose may have been insufficient to inhibit bromazepam metabolism.<sup>2</sup> <br><br>Bromazepam (12 mg single dose) mean Cmax and AUC and elimination half-life increased approximately 4.5-fold, 2.5-fold, and 2-fold respectively with concomitant fluvoxamine (50 mg BID) in twelve healthy subjects,<sup>3</sup> while cimetidine (300 mg QID) decreased bromazepam (6 mg single dose) clearance 50% and increased its half-life 26% in 8 healthy subjects.<sup>4</sup><br><br>The precise isoenzyme(s) responsible for the hepatic oxidative metabolism of bromazepam is(are) not known. CYP3A4 is strongly inhibited by itraconazole and moderately inhibited by fluconazole and cimetidine. Fluvoxamine strongly inhibits CYP2C19 and 1A2 and cimetidine moderately inhibits CYP2D6 and 1A2. The reported observations suggest that CYP isoenymes other than 3A4 may be primarily responsible for bromazepam metabolism and that use of bromazepam may be considered in patients requiring benzodiazepine therapy and receiving a CYP3A4 inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Oda M, Kotegawa T, Tsutsumi K, et al, “The Effect of Itraconazole on the Pharmacokinetics and Pharmacodynamics of Bromazepam in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 2003, 59:615-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14517708\">[PubMed 14517708]</a></p>\n<p>2. Ohtani Y, Kotegawa T, Tsutsumi K, et al, “Effect of Fluconazole on the Pharmacokinetics and Pharmacodynamics of Oral and Rectal Bromazepam: An Application of Electroencephalography as the Pharmacodynamic Method,” <i>J Clin Pharmacol</i>, 2002, 42(2):183-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11831541\">[PubMed 11831541]</a></p>\n<p>3. Van Harten J, Holland RL, and Wesnes K, “Influence of Multiple-Dose Administration of Fluvoxamine on the Pharmacokinetics of the Benzodiazepines Bromazepam and Lorazepam: A Randomised, Cross-Over Study,” <i>Pharmacopsychiatry</i>, 1999, 32(1):29-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10071180\">[PubMed 10071180]</a></p>\n<p>4. Ochs HR, Greenblatt DJ, Friedman H, et al, “Bromazepam Pharmacokinetics: Influence of Age, Gender, Oral Contraceptives, Cimetidine, and Propranolol,” <i>Clin Pharmacol Ther</i>, 1987, 41(5):562-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2882883\">[PubMed 2882883]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5603":"<p><b>Title</b> Bromazepam / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Bromazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In patients receiving fluvoxamine who require benzodiazepine therapy, avoid use of bromazepam if possible and consider use of a benzodiazepine that does not undergo oxidative metabolism (e.g., lorazepam). If bromazepam is initiated in patients receiving fluvoxamine, monitor closely for increased bromazepam levels/adverse effects.</p> \n<p><b>Discussion</b> In a cross-over study of twelve healthy subjects receiving single dose bromazepam (12 mg) or lorazepam (4 mg) with or without fluvoxamine (50 mg BID), concomitant fluvoxamine increased the mean Cmax, AUC, and elimination half-life of bromazepam approximately 4.5-fold, 2.5-fold, and 2-fold and of lorazepam by approximately 6%, 12%, and 12% respectively.<sup>1</sup> An increase in cognitive impairment was noted with both benzodiazepines and concomitant fluvoxamine although the overall increase in impairment was greater with bromazepam. <br><br>Lorazepam undergoes glucuronidation while bromazepam undergoes hepatic oxidative metabolism, although the precise isoenzyme(s) responsible for bromazepam metabolism is not known. An in vivo study of eight healthy subjects demonstrated minimal increases in bromazepam Cmax (4.5%) and AUC (9%) with concomitant administration of itraconazole, a strong CYP3A4 inhibitor.<sup>2</sup> In twelve healthy subjects, nonsignificant bromazepam (3 mg single oral and rectal dose) pharmacokinetic and pharmacodynamic changes were observed following coadministration with fluconazole (100 mg QD), a strong CYP2C9 and 2C19 inhibitor and moderate CYP3A4 inhibitor, though the author suggests the fluconazole dose may have been insufficient to inhibit bromazepam metabolism.<sup>3</sup> <br><br>Fluvoxamine inhibits several CYP isoenzymes and potently inhibits CYP1A2.<sup>4</sup> Although not precisely known, one possible explanation for the observed interaction with bromazepam<sup>1</sup> might include fluvoxamine inhibition of bromazepam metabolism via CYP1A2. In patients receiving fluvoxamine therapy, it may be prudent to consider use of benzodiazepines which do not undergo oxidative metabolism (e.g., lorazepam).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Van Harten J, Holland RL, and Wesnes K, “Influence of Multiple-Dose Administration of Fluvoxamine on the Pharmacokinetics of the Benzodiazepines Bromazepam and Lorazepam: A Randomised, Cross-Over Study,” <i>Pharmacopsychiatry</i>, 1999, 32(1):29-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10071180\">[PubMed 10071180]</a></p>\n<p>2. Oda M, Kotegawa T, Tsutsumi K, et al, “The Effect of Itraconazole on the Pharmacokinetics and Pharmacodynamics of Bromazepam in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 2003, 59:615-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14517708\">[PubMed 14517708]</a></p>\n<p>3. Ohtani Y, Kotegawa T, Tsutsumi K, et al, “Effect of Fluconazole on the Pharmacokinetics and Pharmacodynamics of Oral and Rectal Bromazepam: An Application of Electroencephalography as the Pharmacodynamic Method,” <i>J Clin Pharmacol</i>, 2002, 42(2):183-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11831541\">[PubMed 11831541]</a></p>\n<p>4. Prescribing information. Luvox CR (fluvoxamine). Palo Alto, CA: Jazz Pharmaceuticals, Inc., 02/09.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5604":"<p><b>Title</b> Bromazepam / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Bromazepam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of bromazepam and cimetidine if possible. In patients receiving bromazepam therapy, consider use of an H2-antagonist that is not a potent CYP inhibitor (e.g., ranitidine). Other therapeutic options include the use of cimetidine with a benzodiazepine that does not undergo oxidative metabolism (e.g., lorazepam, oxazepam). If bromazepam and cimetidine are used concomitantly, closely monitor patients for increased bromazepam levels/adverse effects.</p> \n<p><b>Discussion</b> In 8 healthy subjects, coadministration of cimetidine (300 mg QID) and bromazepam (6 mg x1) decreased bromazepam clearance 50% and increased its elimination half-life 26%.<sup>1</sup> Cimetidine likely inhibited the hepatic oxidative metabolism of bromazepam. In some studies, coadministration of bromazepam with strong inhibitors of CYP3A4 (itraconazole)<sup>2</sup> and CYP2C9/2C19 (fluconazole)<sup>3</sup> demonstrated minimal and/or nonsignficant bromazepam pharmacokinetic/pharmacodynamic changes while other studies with strong CYP1A2 inhibitors (fluvoxamine) demonstrated significant increases in bromazepam systemic exposure and elimination half-life.<sup>4</sup> Ciimetidine does inhibit CYP1A2, which might provide a possible explanation for the reported interaction with bromazepam; although, the precise mechanism is not known. For patients requiring concomitant H2-antagonist and benzodiazepine therapy, options might include use of bromazepam with an H2-antagonist that is not a potent CYP inhibitor (e.g., ranitidine) or use of cimetidine with a benzodiazepine that does not go undergo oxidative metabolism (e.g., lorazepam, oxazepam).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ochs HR, Greenblatt DJ, Friedman H, et al, “Bromazepam Pharmacokinetics: Influence of Age, Gender, Oral Contraceptives, Cimetidine, and Propranolol,” <i>Clin Pharmacol Ther</i>, 1987, 41(5):562-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2882883\">[PubMed 2882883]</a></p>\n<p>2. Oda M, Kotegawa T, Tsutsumi K, et al, “The Effect of Itraconazole on the Pharmacokinetics and Pharmacodynamics of Bromazepam in Healthy Volunteers,” <i>Eur J Clin Pharmacol</i>, 2003, 59:615-19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14517708\">[PubMed 14517708]</a></p>\n<p>3. Ohtani Y, Kotegawa T, Tsutsumi K, et al, “Effect of Fluconazole on the Pharmacokinetics and Pharmacodynamics of Oral and Rectal Bromazepam: An Application of Electroencephalography as the Pharmacodynamic Method,” <i>J Clin Pharmacol</i>, 2002, 42(2):183-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11831541\">[PubMed 11831541]</a></p>\n<p>4. Van Harten J, Holland RL, and Wesnes K, “Influence of Multiple-Dose Administration of Fluvoxamine on the Pharmacokinetics of the Benzodiazepines Bromazepam and Lorazepam: A Randomised, Cross-Over Study,” <i>Pharmacopsychiatry</i>, 1999, 32(1):29-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10071180\">[PubMed 10071180]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5605":"<p><b>Title</b> Fosaprepitant / PARoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PARoxetine may decrease serum concentrations of the active metabolite(s) of Fosaprepitant. Fosaprepitant may decrease the serum concentration of PARoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs or symptoms of decreased clinical response to fosaprepitant/aprepitant and/or paroxetine when these agents are used in combination.</p> \n<p><b>Discussion</b> Fosaprepitant is a prodrug of aprepitant and is rapidly converted to aprepitant following administration.<sup>1</sup> According to fosaprepitant prescribing information, coadministration of aprepitant (given once daily as a tablet, approximately equivalent to the 85 mg or 170 mg of the capsule) and paroxetine (20 mg/day) was associated with a mean 25% decrease in the AUC of both aprepitant and paroxetine.<sup>1</sup> The mean maximum serum concentration (Cmax) of both drugs were also each decreased by 20% with coadministration.<br><br>The specific mechanism for this described interaction is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Emend (fosaprepitant). Whitehouse Station, NJ: Merck &amp; Co., Inc., November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5606":"<p><b>Title</b> TOLBUTamide / Fosaprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosaprepitant may decrease the serum concentration of TOLBUTamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor response to tolbutamide closely following concurrent use of fosaprepitant/aprepitant. The concentrations and clinical effectiveness of tolbutamide may be decreased for at least 2 weeks following a single 3-day course of fosaprepitant/aprepitant.</p> \n<p><b>Discussion</b> Fosaprepitant is a prodrug of aprepitant and is rapidly converted to aprepitant following administration.<sup>1</sup> The average tolbutamide AUC was reduced by 23% on day 4, by 28% on day 8, and by 15% on day 15 following concurrent use with aprepitant (125 mg on day 1, 80 mg on day 2, and 80 mg on day 3) versus placebo in a study of 24 healthy volunteers.<sup>2</sup><br><br>The mechanism of this apparent interaction is likely aprepitant-mediated induction of CYP2C9, which is the enzyme primarily responsible for the metabolism of tolbutamide. Other data with aprepitant have also demonstrated the ability of aprepitant to induce CYP2C9, with maximal induction occurring at approximately 7-10 days following initiation of the 3-day aprepitant regimen.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Emend (fosaprepitant). Whitehouse Station, NJ: Merck &amp; Co., Inc., November 2010.</p>\n<p>2. Shadle CR, Lee Y, Majumdar AK, et al, “Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity,” <i>J Clin Pharmacol</i>, 2004, 44:215-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14973304\">[PubMed 14973304]</a></p>\n<p>3. Depre M, Van Hecken A, Oeyen M, et al, “Effect of Aprepitant on the Pharmacokinetics and Pharmacodynamics of Warfarin,” <i>Eur J Clin Pharmacol</i>, 2005, 61:341-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15983826\">[PubMed 15983826]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5607":"<p><b>Title</b> Peginterferon Alfa-2a / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Peginterferon Alfa-2a. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to peginterferon alfa-2a when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5608":"<p><b>Title</b> Peginterferon Alfa-2b / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Peginterferon Alfa-2b. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to peginterferon alfa-2b when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5609":"<p><b>Title</b> Pegademase Bovine / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Pegademase Bovine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to pegademase bovine when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5610":"<p><b>Title</b> Pegaptanib / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Pegaptanib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to pegaptanib when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5611":"<p><b>Title</b> Pegaspargase / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Pegaspargase. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to pegaspargase when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5612":"<p><b>Title</b> Pegfilgrastim / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Pegfilgrastim. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to pegfilgrastim when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5613":"<p><b>Title</b> Pegvisomant / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Pegvisomant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to pegvisomant when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5614":"<p><b>Title</b> Certolizumab Pegol / Pegloticase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pegloticase may diminish the therapeutic effect of Certolizumab Pegol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of diminished clinical response to certolizumab pegol when used with or shortly after pegloticase.</p> \n<p><b>Discussion</b> According to pegloticase prescribing information, 92% of patients receiving pegloticase every 2 weeks developed anti-pegloticase antibodies, and 42% developed anti-PEG (polyethylene glycol) antibodies.<sup>1</sup> Of note, the anti-pegloticase antibodies also appeared to be directed against the PEG portion of the molecule. Though the exact clinical significance of such antibodies remains uncertain, patients with the most circulating antibodies seemed to have higher rates of treatment failure.<sup>1</sup><br><br>It is unknown whether these anti-pegloticase and/or anti-PEG antibodies would impact the clinical effectiveness of other pegylated drug products, but considering the available data, caution is recommended when using other pegylated products with (or immediately following) pegloticase.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Krystexxa (pegloticase). East Brunswick, NJ: Savient Pharmaceuticals, Inc., 09/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5615":"<p><b>Title</b> Acetaminophen / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider limiting the use of acetaminophen in patients who are also taking probenecid. Because probenecid use may be associated with reduced acetaminophen clearance to one of its non-toxic metabolites, patients may be at an increased risk for acetaminophen toxicity, even at lower doses.</p> \n<p><b>Discussion</b> Mean acetaminophen clearance was approximately 45% lower and the mean urinary excretion of acetaminophen glucuronide was 68-79% lower with concurrent probenecid in two separate studies in healthy volunteers.<sup>1,2</sup> Additionally, concurrent probenecid was associated with a mean 72% increase in acetaminophen half-life (4.3 hrs vs. 2.5 hrs).<sup>1</sup><br><br>The results of several in vitro studies support the findings of these studies in healthy volunteers.<sup>3,4,5</sup><br><br>The exact mechanism(s) of this interaction is unknown, but probenecid appears to inhibit the formation, and possibly the excretion, of acetaminophen glucuronide.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Abernethy DR, Greenblatt DJ, Ameer B, et al, “Probenecid Impairment of Acetaminophen and Lorazepam Clearance: Direct Inhibition of Ether Glucuronide Formation,” <i>J Pharmacol Exp Ther</i>, 1985, 234(2):345-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4020675\">[PubMed 4020675]</a></p>\n<p>2. Kamali F, “The Effect of Probenecid on Paracetamol Metabolism and Pharmacokinetics,” <i>Eur J Clin Pharmacol</i>, 1993, 45(6):551-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8157041\">[PubMed 8157041]</a></p>\n<p>3. Turner KC, Brouwer KL, “In Vitro Mechanisms of Probenecid-Associated Alterations in Acetaminophen Glucuronide Hepatic Disposition,” <i>Drug Metab Dispos</i>, 1997, 25(9):1017-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9311615\">[PubMed 9311615]</a></p>\n<p>4. von Moltke LL, Manis M, Harmatz JS, et al, “Inhibition of Acetaminophen and Lorazepam Glucuronidation In Vitro by Probenecid,” <i>Biopharm Drug Dispos</i>, 1993, 14(2):119-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453022\">[PubMed 8453022]</a></p>\n<p>5. Savina PM, Brouwer KL, “Probenecid-Impaired Biliary Excretion of Acetaminophen Glucuronide and Sulfate in the Rat,” <i>Drug Metab Dispos</i>, 1992, 20(4):496-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1356724\">[PubMed 1356724]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5616":"<p><b>Title</b> Tipranavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Tipranavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of rifampin with tipranavir is contraindicated.</p> \n<p><b>Discussion</b> According to tipranavir prescribing information, concurrent use of rifampin is contraindicated due to the possibility of reduced clinical response to tipranavir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5617":"<p><b>Title</b> Rifabutin / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Tipranavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce rifabutin doses during tipranavir coadministration. Tipranavir US labeling recommends a decrease of at least 75%, to 150 mg every other day or 3 times per week. Clinical guidelines recommend 150 mg daily or 300 mg 3 times per week when used with tipranavir/ritonavir. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended.</p> \n<p><b>Discussion</b> The AUC of both rifabutin and its active desacetyl metabolite were an average of 2.9-fold and 20-fold higher, respectively, when rifabutin (150 mg single oral dose) was administered with tipranavir/ritonavir (500 mg/200 mg orally twice daily for 15 doses).<sup>1,2</sup> <br><br>The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by tipranavir/ritonavir. Tipranavir US prescribing information recommends a decrease in rifabutin dose during concomitant treatment to 150 mg every other day or 3 times per week. Clinical guidelines recommend a reduction in rifabutin dose to 150 mg daily or 300 mg 3 times per week when used with any ritonavir-boosted protease inhibitor.<sup>3,4</sup> This latter recommendation is based on data suggesting that rifabutin exposure following doses recommended in US drug labeling may be insufficient when given to patients coinfected with HIV and tuberculosis.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; April 2010.</p>\n<p>2. la Porte CJ, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. <i>Antimicrob Agents Chemother</i>. 2009;53(1):162-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19015362\">[PubMed 19015362]</a></p>\n<p>3. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>4. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 2014. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5618":"<p><b>Title</b> Rifabutin / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Atazanavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce rifabutin doses during atazanavir coadministration. Atazanavir US labeling recommends a decrease of at least 75%, to 150 mg every other day or 3 times per week. Clinical guidelines recommend 150 mg/day or 300 mg 3 times per week when used with atazanavir/ritonavir.</p> \n<p><b>Discussion</b> The average AUC of both rifabutin and its active desacetyl metabolite were more than 2-fold and 22-fold higher, respectively, when rifabutin (300 mg/day on days 1-10 and 150 mg/day on days11-20) was administered with atazanavir (600 mg/day on days 11-20).<sup>1</sup> A study using a lower dose of rifabutin (150 mg twice/week x 15 days) with atazanavir/ritonavir (300 mg/100 mg daily x 17 days) reported a mostly similar, though of somewhat lesser magnitude, increase in the average AUC of both rifabutin and desacetyl-rifabutin (1.5- and 11-fold higher, respectively).<sup>1,2</sup> This study was stopped prior to completion due to rifabutin-associated decreases in neutrophil counts during atazanavir/ritonavir coadministration.<sup>2</sup> Based on simulations, the authors of this study recommended a rifabutin dose of 150 mg every other day or 3 times per week during atazanavir/ritonavir coadministration. However, in an observational study of 16 adults receiving rifabutin 150 mg 3 times per week during atazanavir/ritonavir coadministration, the majority of patients had rifabutin Cmax below the expected lower therapeutic limit (0.3 mcg/mL, 7 patients) and/or minimum plasma concentration below expected <i>Mycobacterium tuberculosis</i> minimum inhibitory concentrations (0.06 mcg/mL, 10 patients).<sup>3</sup><br><br>The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by atazanavir. Atazanavir US prescribing information recommends a decrease in rifabutin dose during concomitant treatment, to 150 mg every other day or 3 times per week. Clinical guidelines recommend a reduction in rifabutin dose to 150 mg per day or 300 mg 3 times per week when used with any ritonavir-boosted protease inhibitor.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb, January 2013.</p>\n<p>2. Zhang J, Zhu L, Stonier M, et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. <i>J Antimicrob Chemothe</i>. 2011;66(9):2075-2082. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21712242\">[PubMed 21712242]</a></p>\n<p>3. Ramachandran G, Bhavani PK, Hemanth Kumar AK, et al. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. <i>Int J Tuberc Lung Dis</i>. 2013;17(12):1564-1568. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24200269\">[PubMed 24200269]</a></p>\n<p>4. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>5. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 2014. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5619":"<p><b>Title</b> Darunavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Darunavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifampin with darunavir is contraindicated.</p> \n<p><b>Discussion</b> According to darunavir prescribing information, concurrent use of rifampin is contraindicated due to the possibility of reduced clinical response to darunavir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, December 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5620":"<p><b>Title</b> Rifabutin / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Darunavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce rifabutin doses during darunavir coadministration. Darunavir US labeling recommends a decrease of at least 75%, to 150 mg every other day or 3 times per week. Clinical guidelines recommend 150 mg/day or 300 mg 3 times per week when used with darunavir/ritonavir. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended.</p> \n<p><b>Discussion</b> In a study comparing the recommended lower-dose rifabutin (150 mg every other day) in combination with darunavir/ritonavir (600 mg/100 mg twice daily) to standard dose rifabutin (300 mg/day), the average AUC of rifabutin was not significantly different, while the AUC of its active desacetyl metabolite was an average of 9.8-fold higher with darunavir/ritonavir coadministration.<sup>1,2</sup> Adverse effects were reported in 83% of patients during rifabutin coadministration with darunavir/ritonavir, compared to 44% and 28% with administration of rifabutin alone and darunavir/ritonavir alone, respectively.<sup>2</sup> The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by darunavir.<br><br>In addition, darunavir concentrations were modestly increased with concurrent rifabutin. Average darunavir AUC and minimum plasma concentration (Cmin) were 57% and 75% higher, respectively, when darunavir/ritonavir (600 mg/100 mg twice daily) and rifabutin (150 mg every other day) were co-administered (n=11).<sup>1</sup> The clinical significance of this apparent interaction is unclear. Likewise the exact mechanism for this interaction is unknown, though inhibition of darunavir metabolism/elimination by rifabutin is suspected.<br><br>Darunavir US prescribing information recommends a decrease in rifabutin dose during concomitant treatment to 150 mg every other day or 3 times per week. Clinical guidelines recommend a reduction in rifabutin dose to 150 mg per day or 300 mg 3 times per week when used with any ritonavir-boosted protease inhibitor.<sup>3,4</sup> This latter recommendation is based on data suggesting that rifabutin exposure following doses recommended in US drug labeling may be insufficient when given to patients coinfected with HIV and tuberculosis.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Prezista</i> (darunavir) [prescribing information]. Raritan, NJ: Tibotec Therapeutics; December 2010.</p>\n<p>2. Sekar V, Lavreys L, Van de Casteele T, et al. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. <i>Antimicrob Agents Chemother</i>. 2010;54(10):4440-4445. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20660678\">[PubMed 20660678]</a></p>\n<p>3. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>4. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 2014. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5621":"<p><b>Title</b> Fosamprenavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifampin with fosamprenavir is contraindicated.</p> \n<p><b>Discussion</b> According to fosamprenavir prescribing information, concurrent use of rifampin (300 mg/day x 4 days) with fosamprenavir (1200 mg twice daily x 4 days) was associated with a mean 82% reduction in fosamprenavir AUC and a mean 92% reduction in fosamprenavir minimum plasma concentrations (Cmin) (n=11).<sup>1</sup> Due to concerns that such reduced fosamprenavir concentrations may lead to reduced clinical response to fosamprenavir, concurrent use of rifampin is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5622":"<p><b>Title</b> Rifabutin / Fosamprenavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Specific dosing adjustments depend on whether or not ritonavir is being used.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosamprenavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may increase the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce rifabutin doses during fosamprenavir coadministration, by at least 50% when used with fosamprenavir alone or 75% (to a dose of 150 mg every other day or 3 times per week) when used with fosamprenavir/ritonavir per US labeling. Clinical guidelines recommend a rifabutin dose of 150 mg/day or 300 mg 3 times per week when used with fosamprenavir/ritonavir and avoidance of rifabutin with unboosted fosamprenavir. Weekly monitoring of complete blood counts is recommended, in addition to otherwise clinically indicated monitoring, in order to monitor for potential neutropenia.</p> \n<p><b>Discussion</b> In a study comparing the recommended lower-dose rifabutin (150 mg every other day) in combination with fosamprenavir/ritonavir (700 mg/100 mg twice daily) to standard dose rifabutin (300 mg daily), the average AUC of rifabutin was not significantly different, while the average AUC of its active desacetyl metabolite was more than 1,000% higher.<sup>1</sup> The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by fosamprenavir.<br><br>In addition, fosamprenavir concentrations were minimally increased with concurrent rifabutin. Average fosamprenavir AUC and minimum plasma concentration (Cmin) were 35% and 17% (nonsignificant) higher, respectively, when fosamprenavir/ritonavir (700 mg/100 mg twice daily) and rifabutin (150 mg every other day) were coadministered (n=15).<sup>1,2</sup> The clinical significance of this apparent interaction is unclear. Likewise the exact mechanism for this interaction is unknown, though inhibition of fosamprenavir metabolism/elimination by rifabutin is suspected.<br><br>Fosamprenavir US prescribing information recommends a decrease in rifabutin dose during concomitant treatment, by at least 50% when used with fosamprenavir alone or 75% (to a dose of 150 mg every other day or 3 times per week) when used with fosamprenavir/ritonavir. Clinical guidelines recommend a rifabutin dose of 150 mg/day or 300 mg 3 times per week when used with fosamprenavir/ritonavir due to data suggesting that rifabutin exposure following doses recommended in US drug labeling may be insufficient in patients coinfected with HIV and tuberculosis.<sup>3,4</sup> Clinical guidelines recommend avoidance of rifabutin with unboosted fosamprenavir due to a lack of data.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lexiva</i> (fosamprenavir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2010.</p>\n<p>2. Ford SL, Chen YC, Lou Y, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. <i>Antimicrob Agents Chemother</i>. 2008;52(2):534-538. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18056271\">[PubMed 18056271]</a></p>\n<p>3. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>4. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. April 2015. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5623":"<p><b>Title</b> Saquinavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. RifAMPin may decrease the serum concentration of Saquinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifampin with saquinavir is contraindicated.</p> \n<p><b>Discussion</b> According to saquinavir prescribing information, concurrent use of rifampin in patients receiving ritonavir-boosted saquinavir is contraindicated due to the risk for severe hepatocellular toxicity.<sup>1</sup><br><br>Of 17 healthy volunteers receiving ritonavir-boosted saquinavir and rifampin, 11 (65%) developed severe hepatocellular toxicity, consisting of increased hepatic transaminase concentrations (to more than 20-fold above the upper limit of normal in some subjects) and gastrointestinal symptoms (e.g., abdominal pain, nausea, vomiting).<sup>1</sup> Transaminase concentrations and gastrointestinal symptoms improved after discontinuation of ritonavir-boosted saquinavir and rifampin.<br><br>The specific mechanism of this apparent interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genetech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5624":"<p><b>Title</b> Rifabutin / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Saquinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may decrease the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce rifabutin doses during saquinavir coadministration. Saquinavir US labeling recommends a decrease of at least 75%, to 150 mg every other day or 3 times per week. Clinical guidelines recommend 150 mg daily or 300 mg 3 times per week when used with saquinavir/ritonavir. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended.</p> \n<p><b>Discussion</b> In a study of lower-dose rifabutin (150 mg every 4 days), the average AUC of active rifabutin compounds (i.e., rifabutin plus desacetyl-rifabutin) was increased 60% with saquinavir/ritonavir (1000 mg/100 mg twice/day) as compared to rifabutin 150 mg/day alone in healthy volunteers.<sup>1,2</sup> The AUC of rifabutin active compounds was around 2.3 fold greater when rifabutin was given at a dose of 150 mg every 3 days in combination with saquinavir/ritonavir compared to rifabutin 150 mg daily given alone in healthy volunteers.<sup>2</sup><br><br>The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by saquinavir (and/or ritonavir). Saquinavir US prescribing information recommends a decrease in rifabutin dose during concomitant treatment to 150 mg every other day or 3 times per week. Clinical guidelines recommend a reduction in rifabutin dose to 150 mg per day or 300 mg 3 times per week when used with any ritonavir-boosted protease inhibitor.<sup>3,4</sup> This latter recommendation is based on data suggesting that rifabutin exposure following doses recommended in US drug labeling may be insufficient when given to patients co-infected with HIV and tuberculosis.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invirase</i> (saquinavir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc; October 2010.</p>\n<p>2. Zhang X, Fettner S, Zwanziger E, Rowell L, Salgo M. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. <i>Antimicrob Agents Chemother</i>. 2011;55(2):680-687. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21135186\">[PubMed 21135186]</a></p>\n<p>3. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>4. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 2014. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5625":"<p><b>Title</b> Indinavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Indinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Rifampin should not be used together with indinavir.</p> \n<p><b>Discussion</b> The average indinavir AUC was reduced by more than 90% with concurrent administration of rifampin (600 mg/day x 8 days) with indinavir (800 mg three times/day x 7 days) (n=12).<sup>1</sup> Due to concerns that such reduced indinavir concentrations may lead to reduced clinical effectiveness, indinavir prescribing information states that rifampin should not be used with indinavir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5626":"<p><b>Title</b> Rifabutin / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Indinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may decrease the serum concentration of Indinavir. Indinavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce the dose of both indinavir and rifabutin if used in combination. According to indinavir US labeling, the rifabutin dose should be reduced by at least 50% when used with indinavir. The dose of indinavir should be increased to 1 g every 8 hours when used with rifabutin. Clinical guidelines recommend a rifabutin dose of 150 mg/day or 300 mg 3 times per week when used with indinavir/ritonavir. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended.</p> \n<p><b>Discussion</b> In a study comparing the recommended lower-dose rifabutin (150 mg daily) in combination with indinavir to standard dose rifabutin (300 mg/day) given alone, the average AUC of rifabutin was around 1.5 fold greater with indinavir coadministration despite the dose reduction.<sup>1,2</sup> The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by indinavir.<br><br>In addition, indinavir concentrations were modestly decreased with concurrent rifabutin. Average indinavir AUC and minimum plasma concentration (Cmin) were 32%-34% and 39%-40% lower, respectively, when indinavir (800 mg three times daily x 10 days) and rifabutin (150-300 mg/day x 10 days) were co-administered (n=10-14).<sup>1,2</sup> The exact mechanism for this interaction is unknown, though induction of indinavir metabolism/elimination by rifabutin is suspected.<br><br>Based on the above changes, indinavir US prescribing information recommends reducing the rifabutin dose by at least 50% and increasing the indinavir dose to 1 g every 8 hours during concomitant treatment.<sup>1</sup> In a clinical study evaluating these dose adjustments, indinavir AUC was similar when given as 800 mg every 8 hours without rifabutin or 1 g every 8 hours with rifabutin (150 mg daily) in HIV infected patients.<sup>3</sup> It was also similar when administered simultaneously with rifabutin or 4 hours after rifabutin in healthy volunteers. AUCs of rifabutin and its desacetyl metabolite were roughly 58%-70% and 107%-117% higher, respectively, when rifabutin was given as a 150 mg daily dose with indinavir (1 g every 8 hours) compared to a 300 mg daily dose without indinavir. Results were again similar whether administration was simultaneous or separated by 4 hours. <br><br>Although specific clinical data are lacking, clinical guidelines propose a rifabutin dose of 150 mg/day or 300 mg 3 times per week when used with indinavir/ritonavir, consistent with rifabutin dosing recommendations without ritonavir.<sup>4,5</sup> This recommendation is based on data suggesting that rifabutin exposure following doses recommended in US drug labeling may be insufficient when given to patients coinfected with HIV and tuberculosis.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Crixivan</i> (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; February 2012.</p>\n<p>2. Kraft WK, McCrea JB, Winchell GA, et al. Indinavir and rifabutin drug interactions in healthy volunteers. <i>J Clin Pharmacol</i>. 2004;44(3):305-313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14973305\">[PubMed 14973305]</a></p>\n<p>3. Hamzeh FM, Benson C, Gerber J, et al; AIDS Clinical Trials Group 365 Study Team. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. <i>Clin Pharmacol Ther</i>. 2003;73(3):159-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12621381\">[PubMed 12621381]</a></p>\n<p>4. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>5. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 2014. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5627":"<p><b>Title</b> Lopinavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. RifAMPin may decrease the serum concentration of Lopinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of rifampin with lopinavir/ritonavir is contraindicated.</p> \n<p><b>Discussion</b> The lopinavir AUC and minimum plasma concentration (Cmin) were reduced by an average of 75% and 99%, respectively, with concurrent administration of rifampin (600 mg/day x 10 days) with lopinavir/ritonavir (400 mg/100 mg twice daily x 20 days) (n=22).<sup>1</sup> Increasing lopinavir/ritonavir doses with concurrent rifampin (600 mg/day) may be able to maintain lopinavir concentrations, as average lopinavir AUC and Cmin were reduced by only 16% and 57%, respectively, with lopinavir/ritonavivr 800 mg/200 mg twice daily (x 9 days) and were not significantly changed with lopinavir/ritonavir 400 mg/400 mg twice daily (x 9 days).<sup>1</sup> However, due to concerns of possible hepatoxicity with this combination (substantial increase in AST/ALT in more than 25% of patients in at least one study), no alternative dosing regimen is recommended, and this combination is contraindicated according to lopinavir/ritonavir prescribing information.<sup>1</sup><br><br>The specific mechanism for the pharmacokinetic interaction is likely rifampin induction of lopinavir metabolism. The mechanism for the potential increase in hepatoxicity is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5628":"<p><b>Title</b> Rifabutin / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lopinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> According to lopinavir/ritonavir prescribing information, the dose of rifabutin should be decreased by at least 75% (i.e., to 150 mg every other day) when used with lopinavir/ritonavir. Based on data suggesting inadequate rifabutin exposure with this adjustment, clinical guidelines instead recommend a rifabutin dose of 150 mg daily or 300 mg every other day in patients receiving lopinavir/ritonavir. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended.</p> \n<p><b>Discussion</b> In a clinical study comparing lower-dose rifabutin (150 mg/day) in combination with lopinavir/ritonavir (400 mg/100 mg twice daily) to standard dose rifabutin (300 mg/day) alone, the average AUC and minimum plasma concentration (Cmin) of rifabutin were 3- and 4.9-fold fold higher, respectively, with the combination.<sup>1</sup> The average AUC of the active desacetyl-rifabutin metabolite was more than 40-fold higher with the combination. The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by lopinavir/ritonavir.<br><br>In addition, lopinavir concentrations were minimally increased with concurrent rifabutin. Average lopinavir AUC and Cmin were 17% and 20% higher, respectively, when lopinavir/ritonavir (400 mg/100 mg twice daily) and rifabutin (150 mg daily) were coadministered (n=14).<sup>1</sup> A published clinical study also found a trend toward lower lopinavir plasma exposure following rifabutin discontinuation,<sup>2</sup> and an analysis of a therapeutic drug monitoring database found a possible association between rifabutin coadministration and increases (a greater than doubling, on average) in lopinavir plasma concentrations.<sup>3</sup> The mechanism of this interaction is not presently clear.<br><br>Based on the above pharmacokinetic changes, lopinavir/ritonavir US prescribing information recommends reducing the rifabutin dose by at least 75% (i.e., to 150 mg every other day) when used with lopinavir/ritonavir. However, one clinical study and a published case series reported rifabutin concentrations frequently below expected therapeutic concentrations using these recommended doses in patients with HIV and tuberculosis coinfection.<sup>4,5</sup> Additionally, a clinical study found that rifabutin 150 mg daily given with lopinavir/ritonavir was associated with only 32% greater average rifabutin concentrations compared to 300 mg daily given alone.<sup>6</sup> Consistent with this, rifabutin 150 mg 3 times a week given with lopinavir/ritonavir was associated with average rifabutin concentrations 44% lower than when rifabutin 300 mg was given daily by itself.<sup>6</sup> In a separate clinical study, rifabutin 150 mg every other day given with lopinavir/ritonavir was associated with a 26% lower average rifabutin AUC when compared to rifabutin 300 mg daily given alone.<sup>7</sup>. Based on these findings, clinical guidelines recommend a rifabutin dose of 150 mg daily or 300 mg 3 times a week in patients concomitantly treated with lopinavir/ritonavir.<sup>8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Kaletra</i> (lopinavir/ritonavir) [prescribing information]. North Chicago, IL: Abbott Laboratories; June 2010.</p>\n<p>2. Matteelli A, Villani P, Carvalho AC, et al. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. <i>J Antimicrob Chemother</i>. 2012;67(10):2470-2473. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22678727\">[PubMed 22678727]</a></p>\n<p>3. Stohr W, Back D, Dunn D, et al; UK CHIC Steering Committee. Factors influencing lopinavir and atazanavir plasma concentration. <i>J Antimicrob Chemother</i>. 2010;65(1):129-137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19897506\">[PubMed 19897506]</a></p>\n<p>4. Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. <i>J Antimicrob Chemother</i>. 2009;64(4):871-873. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19628472\">[PubMed 19628472]</a></p>\n<p>5. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. <i>Clin Infect Dis</i>. 2009;49(9):1305-1311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19807276\">[PubMed 19807276]</a></p>\n<p>6. Lan NT, Thu NT, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. <i>PLoS One</i>. 2014;9(1):e84866. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24465443\">[PubMed 24465443]</a></p>\n<p>7. Tanuma J, Sano K, Teruya K, et al. Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy. <i>PLoS One</i>. 2013;8(8):e70611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23940604\">[PubMed 23940604]</a> </p>\n<p>8. Centers for Disease Control and Prevention (CDC). Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; June 2013. Available at http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/default.htm.</p>\n<p>9. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 2014. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5629":"<p><b>Title</b> Nelfinavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Nelfinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of nelfinavir is contraindicated with rifampin.</p> \n<p><b>Discussion</b> The average nelfinavir AUC and minimum plasma concentration (Cmin) were reduced by 83% and 92% with concurrent administration of rifampin (600 mg/day x 7 days) with nelfinavir (750 mg every 8 hrs x 5-6 days) (n=12).<sup>1</sup> Due to concerns that such reduced nelfinavir concentrations may lead to reduced clinical effectiveness and an increased risk for the development of resistance, nelfinavir prescribing information states that use of nelfinavir is contraindicated with rifampin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5630":"<p><b>Title</b> Rifabutin / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nelfinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Rifabutin may decrease the serum concentration of Nelfinavir. Nelfinavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The doses of both rifabutin and nelfinavir may need to be adjusted if these drugs are to be used in combination. According to nelfinavir prescribing information, the dose of rifabutin should be decreased by at least 50% when used with nelfinavir. Additionally, the preferred dose of nelfinavir when used in combination with rifabutin is 1250 mg twice daily. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended.</p> \n<p><b>Discussion</b> In a study of standard dose rifabutin (300 mg daily for 8 days) in combination with nelfinavir (750 mg every 8 hours for 7-8 days) the average rifabutin AUC and minimum plasma concentration (Cmin) were 146% and 305% higher, respectively, than with rifabutin (300 mg daily) alone.<sup>1</sup> In contrast, the average AUC and Cmin of lower dose rifabutin (150 mg daily) were only increased by 19% and 177%, respectively, with concurrent nelfinavir (750 mg every 8 hours).<sup>1</sup> A similar interaction was reportedly observed with a nelfinavir dose of 1250 mg twice daily.<sup>1</sup> In one study of patients with HIV and tuberculosis co-infection, the AUCs of rifabutin and its main active metabolite desacetyl-rifabutin were increased by 1.2 and 3.5 fold, respectively, when rifabutin (300 mg twice weekly) was given in combination with nelfinavir (1,250 mg twice daily).<sup>2</sup> The specific mechanism for this interaction is uncertain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by nelfinavir.<br><br>In addition, nelfinavir concentrations were modestly decreased with concurrent rifabutin. Average nelfinavir AUC and Cmin were 18%-24% and 25%-53% lower, respectively, when nelfinavir (750 mg every 8 hours) and rifabutin (150-300 mg daily) were coadministered.<sup>1</sup> When the nelfinavir dose was increased to 1250 mg twice daily, no significant change in nelfinavir AUC or Cmin were observed.<sup>1</sup> The exact mechanism for this interaction is unknown, though induction of nelfinavir metabolism/elimination by rifabutin is suspected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Viracept</i> (nelfinavir) [prescribing information]. La Jolla, CA: Agouron Pharmaceuticals, Inc; May 2013.</p>\n<p>2. Benator DA, Weiner MH, Burman WJ, et al; Tuberculosis Trials Consortium. . Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. <i>Pharmacotherapy</i>. 2007;27(6):793-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17542762\">[PubMed 17542762]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5631":"<p><b>Title</b> Ritonavir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Ritonavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to concerns of possible reduced clinical effectiveness, alternatives to rifampin (e.g., rifabutin) should be considered for use with ritonavir whenever possible. Of note, use of other protease inhibitors with rifampin is contraindicated or not recommended, which is of significance to ritonavir for any use in a “ritonavir-boosted” regimen. Additionally, concerns about potential hepatoxicity also support the specific avoidance of saquinavir/ritonavir or lopinavir/ritonavir with rifampin.</p> \n<p><b>Discussion</b> The average ritonavir AUC and minimum plasma concentration (Cmin) were reduced by 35% and 49% with concurrent administration of rifampin (600 mg/day or 300 mg/day x 10 days) with ritonavir (500 mg every 12 hrs x 20 days).<sup>1</sup> Due to concerns that such reduced ritonavir concentrations may lead to reduced clinical effectiveness, alternatives to rifampin (e.g., rifabutin) should be considered for use with ritonavir whenever possible.<sup>1</sup><br><br>Of note, use of other protease inhibitors with rifampin is contraindicated or not recommended, which is of significance to ritonavir for any use in a “ritonavir-boosted” regimen. Additionally, concerns about potential hepatoxicity also support the specific avoidance of saquinavir/ritonavir or lopinavir/ritonavir with rifampin.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, April 2010.</p>\n<p>2. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genetech USA, Inc., 10/2010.</p>\n<p>3. Prescribing information. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5632":"<p><b>Title</b> Rifabutin / Ritonavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Dose adjustment recommendations may vary if ritonavir is used to increase exposure to another protease inhibitor as opposed to being used alone. Refer to drug interaction monographs addressing coadministered protease inhibitors for specific recommendations.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> According to ritonavir prescribing information, the dose of rifabutin should be decreased by at least 75% (i.e., to 150 mg every other day) when used with ritonavir. Increased monitoring for signs/symptoms of toxicity and of clinical response to therapy is also recommended. Refer to drug interaction monographs addressing concomitantly administered protease inhibitors for dosing recommendations when rifabutin is used with ritonavir-boosted regimens.</p> \n<p><b>Discussion</b> In a study of lower-dose rifabutin (150 mg daily for 16 days), the average AUC and minimum plasma concentration (Cmin) of rifabutin was increased 4-fold and 6-fold, respectively, with concurrent ritonavir (500 mg every 12 hours for 10 days) (n=5-11).<sup>1,2</sup> The average AUC of the active desactyl-rifabutin metabolite was 38-fold higher with concurrent ritonavir.<br><br>The specific mechanism for this interaction is not certain but appears to be at least in part due to inhibition of CYP3A-mediated rifabutin metabolism by ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Norvir</i> (ritonavir) [prescribing information]. North Chicago, IL: Abbott Laboratories; November 2013.</p>\n<p>2. Cato A 3rd, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. <i>Clin Pharmacol Ther</i>. 1998;63(4):414-421. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9585795\">[PubMed 9585795]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5634":"<p><b>Title</b> Adenosine / Digoxin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Digoxin may enhance the adverse/toxic effect of Adenosine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution when these agents are used in combination. Monitor patients closely for signs of adverse cardiovascular effects, and particularly for evidence of heart block and/or ventricular fibrillation.</p> \n<p><b>Discussion</b> Adenosine prescribing information warns that most of the reported cases of ventricular fibrillation have been with concurrent digoxin.<sup>1</sup> Though a specific interaction between adenosine and digoxin has not been established, caution is recommended when using these agents in combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adenocard (adenosine). Deerfield, IL: Astellas Pharma US, Inc., 11/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5635":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Buprenorphine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Buprenorphine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> One case report describes a patient on tricyclic antidepressants who developed serotonin syndrome after taking a single dose of unprescribed buprenorphine/naloxone.<sup>1</sup> The patient's symptoms improved following treatment with serotonin receptor antagonist cyproheptadine. This report is in contrast to animal and other experimental data that reported no significant serotonergic effects for buprenorphine and predicted a low risk of serotonin syndrome interactions.<sup>2,3</sup><br><br>Also, of note, the buprenorphine prescribing information does not list monoamine oxidase inhibitors as a possible drug interaction, but the associated medication guide does warn patients not to take buprenorphine within 14 days of a monoamine oxidase inhibitor.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Isenberg D, Wong SC, Curtis JA, “Serotonin Syndrome Triggered by a Single Dose of Suboxone,” <i>Am J Emerg Med</i>, 2008, 26(7):840.e3-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18774063\">[PubMed 18774063]</a></p>\n<p>2. Gillman PK, “Monoamine Oxidase Inhibitors, Opioid Analgesics and Serotonin Toxicity,” <i>Br J Anaesth</i>, 2005, 95(4):434-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p>3. Mackenzie JE, Frank LW, “Influence of Pretreatment with a Monoamine Oxidase Inhibitor (Phenelzine) on the Effects of Buprenorphine and Pethidine in the Conscious Rabbit,” <i>Br J Anaesth</i>, 1988, 60(2):216-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3345281\">[PubMed 3345281]</a></p>\n<p>4. Medication guide. Butrans (buprenorphine). Stamford, CT: Purdue Pharma L.P., August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5636":"<p><b>Title</b> Nitroglycerin / Aspirin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is not expected with oral aspirin doses less than or equal to 500 mg every other day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aspirin may increase the serum concentration of Nitroglycerin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Vasodilatory and hemodynamic effects of nitroglycerin may be enhanced in patients receiving aspirin.</p> \n<p><b>Discussion</b> Prescribing information for nitroglycerin states that coadministration with aspirin has been reported to increase nitroglycerin single-dose maximum concentration and AUC by as much as 67% and 73%, respectively.<sup>1</sup> A clinical study in 7 healthy volunteers showed a significant increase in single-dose nitroglycerin (0.8 mg single sublingual dose) concentrations with 1g aspirin pretreatment (1 hour prior to nitroglycerin) but not with a lower dose regimen (500 mg every other day for 8 days).<sup>2</sup> A similar report showed increases in maximum concentration and AUC of nitroglycerin consistent with the data cited in nitroglycerin prescribing information, again with the higher (1 g) acute aspirin dose but not the lower (500 mg) dose given every other day.<sup>3</sup><br><br>The mechanism by which aspirin may increase nitroglycerin concentrations is unknown. Pharmacodynamic effects consistent with increased nitroglycerin concentrations (e.g. greater decreases in diastolic pressure) have been demonstrated, and prescribing information includes a statement that vasodilatory and hemodynamic effects of nitroglycerin may be enhanced.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nitromist (nitroglycerin). Cranford, NJ: Akrimax Pharmaceuticals, LLC, November 2010.</p>\n<p>2. Weber S, Rey E, Pipeau C, Lutfalla G, et al, “Influence of Aspirin on the Hemodynamic Effects of Sublingual Nitroglycerin,” <i>J Cardiovasc Pharmacol</i>, 1983, 5(5):874-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6195479\">[PubMed 6195479]</a></p>\n<p>3. Rey E, El-Assaf HD, Richard MO, et al, “Pharmacological Interaction Between Nitroglycerin and Aspirin After Acute and Chronic Aspirin Treatment of Healthy Subjects,” <i>Eur J Clin Pharmacol</i>, 1983, 25(6):779-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6420164\">[PubMed 6420164]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5637":"<p><b>Title</b> Phenytoin / CeFAZolin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CeFAZolin may decrease the protein binding of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for altered serum (free/unbound) concentrations/effects of phenytoin if cefazolin is initiated/dose increased.</p> \n<p><b>Discussion</b> In a retrospective review of phenytoin concentrations in critically ill children, 3 patients receiving cefazolin had significantly (85%) higher free phenytoin fraction than control patients.<sup>1</sup> The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wolf GK, McClain CD, Zurakowski D, et al, “Total Phenytoin Concentrations do not Accurately Predict Free Phenytoin Concentrations in Critically Ill Children,” <i>Pediatr Crit Care Med</i>, 2006, 7(5):434-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16885794\">[PubMed 16885794]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5638":"<p><b>Title</b> Vaccines (Live) / Methotrexate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction increases with methotrexate doses greater than 0.4 mg/kg/week.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Methotrexate may enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended vaccinations prior to initiation of immunosuppressant therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Of note, the risk of clinically significant immunosuppression is considered likely to be dose- and drug-dependent. Consistent with this, the American College of Rheumatology specifically does not recommend avoiding any live vaccine in patients being treated with low-dose methotrexate. The Advisory Committee on Immunization Practices (ACIP) specifically notes that therapy with low-doses of methotrexate (0.4 mg/kg/week or less) is generally not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a strict contraindication for administration of zoster vaccine. <br><br>Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> According to these recommendations, all persons receiving chemotherapy or radiation for leukemia or other hematopoetic malignancies, solid tumors, or after solid organ transplantation should be considered to be potentially immunosuppressed. Additionally, the recommendations state that live vaccines should even be avoided with low-dose and/or intermittent use of immunosuppressant drugs unless the potential benefit outweighs the risk.<sup>12</sup><br><br>Of note, ACIP recommendations acknowledge that the risk of clinically significant immunosuppression is likely dose- and drug-dependent.<sup>12</sup> Consistent with this factor, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with hydroxychloroquine, leflunomide, or methotrexate.<sup>13</sup> Similarly, the ACIP recommendations on the prevention of Herpes Zoster state that therapy with low-doses of methotrexate (0.4 mg/kg/week or less), azathioprine (3.0 mg/kg/day or less), or 6-mercaptopurine (1.5 mg/kg/day or less) are not sufficiently immunosuppressive to create safety concerns and are not contraindications for administration of the zoster vaccine.<sup>14</sup> Systemic corticosteroids also appear subject to dose- and duration-dependency regarding their immunosuppressant effects.<sup>12</sup> With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J, “Methotrexate and Smallpox Vaccination,” <i>Lancet</i>, 1968, ii:1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, and Glatstein HR, “Vaccination of a Patient Receiving Immunosuppressive Therapy for Lymphosarcoma,” <i>JAMA</i>, 1966, 198:737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW, “Routine Immunization of the Immunocompromised Child,” <i>Adv Pediatr Infect Dis</i>, 1987, 2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, et al, “Vaccine-Associated Poliomyelitis in a Child with Sex-Linked Agammaglobulinemia,” <i>J Pediatr</i>, 1977, 91:408-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV, “Poliomyelitis in Hypogammaglobulinemics,” <i>J Infect Dis</i>, 1973, 128:802-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, et al, “Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child,” <i>N Engl J Med</i>, 1977, 297:241-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. CDC, “Disseminated Mycobacterium bovis Infection from BCG Vaccination of a Patient with Acquired Immunodeficiency Syndrome,” <i>MMWR</i>, 1985, 34:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, et al, “Disseminated BCG in HIV Infection,” <i>Arch Dis Child</i>, 1988, 63:1268-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, et al, “Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease,” <i>N Engl J Med</i>, 1987, 316:673-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. CDC, “Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993,” <i>MMWR</i>, 1996, 45:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. Kroger AT, Atkinson WL, Marcuse EK, et al, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR</i>, 2006, 55(RR-15):1-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136024\">[PubMed 17136024]</a></p>\n<p>13. Saag KG, Teng GG, Patkar NM, et al, “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 2008, 59(6):762-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512708\">[PubMed 18512708]</a></p>\n<p>14. Harpaz R, Ortega-Sanchez IR, Seward JF, et al, “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2008, 57(RR-5):1-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528318\">[PubMed 18528318]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5641":"<p><b>Title</b> PHENobarbital / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of PHENobarbital. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> In patients receiving phenobarbital, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing phenobarbital dose by 20%. Monitor for increased concentrations/toxic effects of phenobarbital and decreased concentrations/therapeutic effects of felbamate.</p> \n<p><b>Discussion</b> The AUC of phenobarbital (100 mg/day) was increased by approximately 25% in 24 healthy volunteers within 10 days of initiating felbamate (1200 mg twice daily).<sup>1</sup> A 30% increase in phenobarbital concentrations was noted in 19 patients (taking either phenobarbital or primidone, which is metabolized to phenobarbital) following the addition of felbamate.<sup>2</sup> A case report describes a man who was hospitalized due to lethargy, ataxia, and anorexia 5 weeks after addition of felbamate to his regimen of phenobarbital and valproic acid.<sup>3</sup> The man's phenobarbital concentrations had increased by roughly 50% since felbamate initiation.<br><br>According to a study cited in felbamate prescribing information, steady-state plasma felbamate concentrations were 29% lower in patients receiving felbamate with phenobarbital than in patients receiving felbamate only.<sup>4</sup><br><br>The mechanisms of these interactions have not been investigated. Increases in phenobarbital concentrations likely occur due to felbamate inhibition of CYP2C19 mediated phenobarbital metabolism. Felbamate concentrations may be reduced due to phenobarbital induction of CYP3A4 mediated felbamate metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reidenberg P, Glue P, Banfield C, et al, “Effects of Felbamate on the Pharmacokinetics of Phenobarbital,” <i>Clin Pharmacol Ther</i>, 1995, 58:279-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7554701\">[PubMed 7554701]</a></p>\n<p>2. Kerrick JM, Wolff DL, Risinger MW, et al, “Increased Phenobarbital Plasma Concentrations After Felbamate Initiation,” <i>Epilepsia</i>, 1994, 35(Suppl 8):96.</p>\n<p>3. Gidal BE and Zupanc ML, “Potential Pharmacokinetic Interaction Between Felbamate and Phenobarbital,” <i>Ann Pharmacother</i>, 1994, 28:455-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8038465\">[PubMed 8038465]</a></p>\n<p>4. Prescribing information. Felbatol (felbamate). Somerset, NJ: Meda Pharmaceuticals Inc., 6/08.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5642":"<p><b>Title</b> Felbamate / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> In patients receiving carbamazepine, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing carbamazepine dose by 20%. Monitor for reduced concentrations/effects of both drugs.</p> \n<p><b>Discussion</b> In clinical studies in 22 patients receiving chronic carbamazepine (adjusted to morning plasma concentrations of 4-12 mcg/mL), addition of felbamate (titrated up to 3,000 mg daily) decreased steady-state carbamazepine concentrations by 24% compared to placebo.<sup>1</sup> Plasma concentrations of carbamazepine epoxide were increased by approximately 46% in 4 patients who had metabolite concentrations measured. There was no apparent change in carbamazepine or metabolite protein binding. A number of additional studies and case reports have demonstrated similar changes in carbamazepine and metabolite concentrations, or consistent changes in other pharmacokinetic variables, in adults and children receiving felbamate coadministration.<sup>2,3,4,5,6,7</sup><br><br>In addition to the effects of felbamate on carbamazepine pharmacokinetics, carbamazepine administration has been associated with 32-49% increases in felbamate clearance in adults and children.<sup>8,9</sup><br><br>Based on in vitro data, felbamate may increase clearance of carbamazepine to its epoxide via CYP3A4 heteroactivation (not induction).<sup>10</sup> Carbamazepine likely induces CYP3A4 mediated felbamate metabolism. Carbamazepine discontinuation would be expected to result in an increase in felbamate concentrations, and this is supported by some limited case reports.<sup>11</sup> Similarly, discontinuation of felbamate would be expected to result in increases in carbamazepine concentrations. In patients receiving carbamazepine, felbamate prescribing information recommends initiating felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing carbamazepine dose by 20%.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Albani F, Theodore WH, Washington P, et al, “Effect of Felbamate on Plasma Levels of Carbamazepine and its Metabolites,” <i>Epilepsia</i>, 1991, 32(1):130-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1985822\">[PubMed 1985822]</a></p>\n<p>2. Graves NM, Holmes GB, Fuerst RH, et al, “Effect of Felbamate on Phenytoin and Carbamazepine Serum Concentrations,” <i>Epilepsia</i>, 1989, 30(2):225-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2647472\">[PubMed 2647472]</a></p>\n<p>3. Wagner ML, Remmel RP, Graves NM, et al, “Effect of Felbamate on Carbamazepine and its Major Metabolites,” <i>Clin Pharmacol Ther</i>, 1993, 53(5):536-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8491065\">[PubMed 8491065]</a></p>\n<p>4. Graves NM, Brundage RC, Wen Y, et al, “Population Pharmacokinetics of Carbamazepine in Adults With Epilepsy,” <i>Pharmacotherapy</i>, 1998, 18(2):273-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9545146\">[PubMed 9545146]</a></p>\n<p>5. Graves NM, Ludden TM, Holmes GB, et al, “Pharmacokinetics of Felbamate, a Novel Antiepileptic Drug: Application of Mixed-Effect Modeling to Clinical Trials,” <i>Pharmacotherapy</i>, 1989, 9(6):372-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2694113\">[PubMed 2694113]</a></p>\n<p>6. Fuerst RH, Graves NM, Leppik IE, et al, “Felbamate Increases Phenytoin but Decreases Carbamazepine Concentrations,” <i>Epilepsia</i>, 1988, 29(4):488-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3391153\">[PubMed 3391153]</a></p>\n<p>7. Prescribing information. Felbatol (felbamate). Somerset, NJ: Meda Pharmaceuticals Inc., 6/08.</p>\n<p>8. Banfield CR, Zhu GR, Jen JF, et al, “The Effect of Age on the Apparent Clearance of Felbamate: A Retrospective Analysis Using Nonlinear Mixed-Effects Modeling,” <i>Ther Drug Monit</i>, 1996, 18(1):19-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8848816\">[PubMed 8848816]</a></p>\n<p>9. Kelley MT, Walson PD, Cox S, et al, “Population Pharmacokinetics of Felbamate in Children,” <i>Ther Drug Monit</i>, 1997, 19(1):29-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9029743\">[PubMed 9029743]</a></p>\n<p>10. Egnell AC, Houston B and Boyer S, “In Vivo CYP3A4 Heteroactivation is a Possible Mechanism for the Drug Interaction Between Felbamate and Carbamazepine,” <i>J Pharmacol Exp Ther</i>, 2003, 305(3):1251-62. Epub 2003 Jan 24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12606595\">[PubMed 12606595]</a></p>\n<p>11. Wagner ML, Graves NM, Marienau K, et al, “Discontinuation of Phenytoin and Carbamazepine in Patients Receiving Felbamate,” <i>Epilepsia</i>, 1991, 32(3):398-406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1904346\">[PubMed 1904346]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5643":"<p><b>Title</b> Estrogen Derivatives / Ascorbic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ascorbic Acid may increase the serum concentration of Estrogen Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> The clinical significance of the rise in plasma concentrations due to concurrent use of estradiol and ascorbic acid has not been ascertained. Increased plasma levels of estradiol may increase the risk of adverse effects associated with estradiol use. However, since the use of estradiol is commonly dosed based on relief of symptoms and usually administered in the lowest effective dose, the management of this interaction may only require more frequent evaluation of estrogenic side effects in those patients initially deficient in vitamin C or estradiol. In addition, it may be prudent to counsel patients using ethinyl estradiol for contraception to not substantially vary their intake of ascorbic acid, or to use a back-up method of contraception for seven days after sudden discontinuation of ascorbic acid, as there is a theoretical risk of contraceptive failure with fluctuating levels of ethinyl estradiol throughout the cycle.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> A small number of studies have found that the plasma concentration of estradiols may be increased in women also taking ascorbic acid in doses of 1 gram per day, with great variability between subjects.<sup>1,2</sup> In one study with five healthy volunteers each serving as their own controls, the plasma concentration of orally administered ethinyl estradiol increased by an average of 16.3% (range 10.8-26.2%) six hours post-dose and by an average of 47.6% (range 22.2-100%) twenty-four hours post dose.<sup>2</sup> In a second study, transdermal estradiol was the source of estradiol. The overall average increase in plasma concentrations of estradiol was 20.8%; however, a subgroup analysis of this study suggests that this effect may be more pronounced in women with lower concentrations of either estradiol or ascorbic acid, with average increases of 55% and 100%, respectively.<sup>1</sup> A case report of a patient who experienced episodes of breakthrough bleeding that corresponded with self-administration and then discontinuation of 1 gram of ascoribic acid supports these findings.<sup>3</sup> Based on the case report, it was suggested that the breakthrough bleeding was a result of the subsequent drop in elevated estradiol. Another study found no significant changes in ethinyl estradiol concentrations with concurrent ascorbic acid, but did report significantly decreased concentrations of the metabolite ethinyl estradiol-sulfate with concurrent ascorbic acid; however, there was a large degree of variability in the results.<sup>4</sup> This may be due to natural interpersonal variability in sulfation, the pathway by which both estradiol and ascorbic acid are metabolized.<br><br>Ethinyl estradiol (oral) and estradiol (topical) are both inactivated and excreted through hepatic metabolism, with sulfation playing an important role. Ascorbic acid also undergoes sulfation and is usually taken in much larger relative doses than is estradiol, creating a theoretical interaction via competition for metabolism and increasing the concentration of active hormone in plasma.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vihtamaki T, Parantainen J, Koivisto AM, et al, “Oral Ascorbic Acid Increases Plasma Oestradiol During Postmenopausal Hormone Replacement Therapy,” <i>Maturitas</i>, 2002, 42:129-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12065172\">[PubMed 12065172]</a></p>\n<p>2. Back DJ, Breckenridge AM, MacIver M, et al, “Interaction of Ethinylestradiol with Ascorbic Acid in Man,” <i>Br Med J</i>, 1981, 282:1516. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6786543\">[PubMed 6786543]</a></p>\n<p>3. Morris JC, Beeley L, Ballantine N, “Interaction of Ethinylestradiol with Ascorbic Acid in Man,” <i>Br Med J (Clin Res Ed)</i>, 1981, 283(6289):503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6790042\">[PubMed 6790042]</a></p>\n<p>4. Zamah NM, Humpel M, Kuhnz W, et al, “Absence of an Effect of High Vitamin C Dosage on the Systemic Availability of Ethinyl Estradiol in Women Using a Combination Oral Contraceptive,” <i>Contraception</i>, 1993, 48:377-391. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8222665\">[PubMed 8222665]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5645":"<p><b>Title</b> Vaccines (Live) / Leflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Leflunomide may enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended vaccinations prior to initiation of immunosuppressant therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Of note, the risk of clinically significant immunosuppression is considered likely to be dose- and drug-dependent. Consistent with this, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with leflunomide. <br><br>Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> According to these recommendations, all persons receiving chemotherapy or radiation for leukemia or other hematopoetic malignancies, solid tumors, or after solid organ transplantation should be considered to be potentially immunosuppressed. Additionally, the recommendations state that live vaccines should even be avoided with low-dose and/or intermittent use of immunosuppressant drugs unless the potential benefit outweighs the risk.<sup>12</sup><br><br>Of note, ACIP recommendations acknowledge that the risk of clinically significant immunosuppression is likely dose- and drug-dependent.<sup>12</sup> Consistent with this factor, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with hydroxychloroquine, leflunomide, or methotrexate.<sup>13</sup> Similarly, the ACIP recommendations on the prevention of Herpes Zoster state that therapy with low-doses of methotrexate (0.4 mg/kg/week or less), azathioprine (3.0 mg/kg/day or less), or 6-mercaptopurine (1.5 mg/kg/day or less) are not sufficiently immunosuppressive to create safety concerns and are not contraindications for administration of the zoster vaccine.<sup>14</sup> Systemic corticosteroids also appear subject to dose- and duration-dependency regarding their immunosuppressant effects.<sup>12</sup> With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J, “Methotrexate and Smallpox Vaccination,” <i>Lancet</i>, 1968, ii:1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, and Glatstein HR, “Vaccination of a Patient Receiving Immunosuppressive Therapy for Lymphosarcoma,” <i>JAMA</i>, 1966, 198:737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW, “Routine Immunization of the Immunocompromised Child,” <i>Adv Pediatr Infect Dis</i>, 1987, 2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, et al, “Vaccine-Associated Poliomyelitis in a Child with Sex-Linked Agammaglobulinemia,” <i>J Pediatr</i>, 1977, 91:408-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV, “Poliomyelitis in Hypogammaglobulinemics,” <i>J Infect Dis</i>, 1973, 128:802-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, et al, “Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child,” <i>N Engl J Med</i>, 1977, 297:241-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. CDC, “Disseminated Mycobacterium bovis Infection from BCG Vaccination of a Patient with Acquired Immunodeficiency Syndrome,” <i>MMWR</i>, 1985, 34:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, et al, “Disseminated BCG in HIV Infection,” <i>Arch Dis Child</i>, 1988, 63:1268-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, et al, “Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease,” <i>N Engl J Med</i>, 1987, 316:673-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. CDC, “Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993,” <i>MMWR</i>, 1996, 45:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. Kroger AT, Atkinson WL, Marcuse EK, et al, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR</i>, 2006, 55(RR-15):1-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136024\">[PubMed 17136024]</a></p>\n<p>13. Saag KG, Teng GG, Patkar NM, et al, “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 2008, 59(6):762-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512708\">[PubMed 18512708]</a></p>\n<p>14. Harpaz R, Ortega-Sanchez IR, Seward JF, et al, “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2008, 57(RR-5):1-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528318\">[PubMed 18528318]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5646":"<p><b>Title</b> Vaccines (Live) / AzaTHIOprine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction increases with azathioprine doses greater than 3 mg/kg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> AzaTHIOprine may enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended vaccinations prior to initiation of immunosuppressant therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Of note, the risk of clinically significant immunosuppression is considered likely to be dose- and drug-dependent. Consistent with this, therapy with low-doses of azathioprine (3 mg/kg/day or less) is generally not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a strict contraindication for administration of zoster vaccine. <br><br>Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> According to these recommendations, all persons receiving chemotherapy or radiation for leukemia or other hematopoetic malignancies, solid tumors, or after solid organ transplantation should be considered to be potentially immunosuppressed. Additionally, the recommendations state that live vaccines should even be avoided with low-dose and/or intermittent use of immunosuppressant drugs unless the potential benefit outweighs the risk.<sup>12</sup><br><br>Of note, ACIP recommendations acknowledge that the risk of clinically significant immunosuppression is likely dose- and drug-dependent.<sup>12</sup> Consistent with this factor, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with hydroxychloroquine, leflunomide, or methotrexate.<sup>13</sup> Similarly, the ACIP recommendations on the prevention of Herpes Zoster state that therapy with low-doses of methotrexate (0.4 mg/kg/week or less), azathioprine (3.0 mg/kg/day or less), or 6-mercaptopurine (1.5 mg/kg/day or less) are not sufficiently immunosuppressive to create safety concerns and are not contraindications for administration of the zoster vaccine.<sup>14</sup> Systemic corticosteroids also appear subject to dose- and duration-dependency regarding their immunosuppressant effects.<sup>12</sup> With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J, “Methotrexate and Smallpox Vaccination,” <i>Lancet</i>, 1968, ii:1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, and Glatstein HR, “Vaccination of a Patient Receiving Immunosuppressive Therapy for Lymphosarcoma,” <i>JAMA</i>, 1966, 198:737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW, “Routine Immunization of the Immunocompromised Child,” <i>Adv Pediatr Infect Dis</i>, 1987, 2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, et al, “Vaccine-Associated Poliomyelitis in a Child with Sex-Linked Agammaglobulinemia,” <i>J Pediatr</i>, 1977, 91:408-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV, “Poliomyelitis in Hypogammaglobulinemics,” <i>J Infect Dis</i>, 1973, 128:802-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, et al, “Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child,” <i>N Engl J Med</i>, 1977, 297:241-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. CDC, “Disseminated Mycobacterium bovis Infection from BCG Vaccination of a Patient with Acquired Immunodeficiency Syndrome,” <i>MMWR</i>, 1985, 34:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, et al, “Disseminated BCG in HIV Infection,” <i>Arch Dis Child</i>, 1988, 63:1268-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, et al, “Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease,” <i>N Engl J Med</i>, 1987, 316:673-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. CDC, “Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993,” <i>MMWR</i>, 1996, 45:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. Doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. Kroger AT, Atkinson WL, Marcuse EK, et al, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR</i>, 2006, 55(RR-15):1-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136024\">[PubMed 17136024]</a></p>\n<p>13. Saag KG, Teng GG, Patkar NM, et al, “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 2008, 59(6):762-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512708\">[PubMed 18512708]</a></p>\n<p>14. Harpaz R, Ortega-Sanchez IR, Seward JF, et al, “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2008, 57(RR-5):1-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528318\">[PubMed 18528318]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5647":"<p><b>Title</b> Vaccines (Live) / Mercaptopurine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction increases with 6-mercaptopurine doses greater than 1.5 mg/kg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mercaptopurine may enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended vaccinations prior to initiation of immunosuppressant therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Of note, the risk of clinically significant immunosuppression is considered likely to be dose- and drug-dependent. Consistent with this, therapy with low-doses of 6-mercaptopurine (1.5 mg/kg/day or less) is generally not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a strict contraindication for administration of zoster vaccine. <br><br>Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> According to these recommendations, all persons receiving chemotherapy or radiation for leukemia or other hematopoetic malignancies, solid tumors, or after solid organ transplantation should be considered to be potentially immunosuppressed. Additionally, the recommendations state that live vaccines should even be avoided with low-dose and/or intermittent use of immunosuppressant drugs unless the potential benefit outweighs the risk.<sup>12</sup><br><br>Of note, ACIP recommendations acknowledge that the risk of clinically significant immunosuppression is likely dose- and drug-dependent.<sup>12</sup> Consistent with this factor, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with hydroxychloroquine, leflunomide, or methotrexate.<sup>13</sup> Similarly, the ACIP recommendations on the prevention of Herpes Zoster state that therapy with low-doses of methotrexate (0.4 mg/kg/week or less), azathioprine (3.0 mg/kg/day or less), or 6-mercaptopurine (1.5 mg/kg/day or less) are not sufficiently immunosuppressive to create safety concerns and are not contraindications for administration of the zoster vaccine.<sup>14</sup> Systemic corticosteroids also appear subject to dose- and duration-dependency regarding their immunosuppressant effects.<sup>12</sup> With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J, “Methotrexate and Smallpox Vaccination,” <i>Lancet</i>, 1968, ii:1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, and Glatstein HR, “Vaccination of a Patient Receiving Immunosuppressive Therapy for Lymphosarcoma,” <i>JAMA</i>, 1966, 198:737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW, “Routine Immunization of the Immunocompromised Child,” <i>Adv Pediatr Infect Dis</i>, 1987, 2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, et al, “Vaccine-Associated Poliomyelitis in a Child with Sex-Linked Agammaglobulinemia,” <i>J Pediatr</i>, 1977, 91:408-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV, “Poliomyelitis in Hypogammaglobulinemics,” <i>J Infect Dis</i>, 1973, 128:802-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, et al, “Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child,” <i>N Engl J Med</i>, 1977, 297:241-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. CDC, “Disseminated Mycobacterium bovis Infection from BCG Vaccination of a Patient with Acquired Immunodeficiency Syndrome,” <i>MMWR</i>, 1985, 34:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, et al, “Disseminated BCG in HIV Infection,” <i>Arch Dis Child</i>, 1988, 63:1268-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, et al, “Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease,” <i>N Engl J Med</i>, 1987, 316:673-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. CDC, “Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993,” <i>MMWR</i>, 1996, 45:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. Kroger AT, Atkinson WL, Marcuse EK, et al, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR</i>, 2006, 55(RR-15):1-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136024\">[PubMed 17136024]</a></p>\n<p>13. Saag KG, Teng GG, Patkar NM, et al, “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 2008, 59(6):762-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512708\">[PubMed 18512708]</a></p>\n<p>14. Harpaz R, Ortega-Sanchez IR, Seward JF, et al, “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2008, 57(RR-5):1-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528318\">[PubMed 18528318]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5648":"<p><b>Title</b> Vaccines (Live) / Corticosteroids (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Clinical significance of this interaction is increased with higher corticosteroid doses and longer duration of therapy.</p></li>\n <li><p><b>Duration</b>: Clinical significance of this interaction is increased with higher corticosteroid doses and longer duration of therapy.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended vaccinations prior to initiation of immunosuppressant therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Of note, systemic corticosteroids are subject to dose- and duration-dependency regarding their immunosuppressant effects. With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<br><br>Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> According to these recommendations, all persons receiving chemotherapy or radiation for leukemia or other hematopoetic malignancies, solid tumors, or after solid organ transplantation should be considered to be potentially immunosuppressed. Additionally, the recommendations state that live vaccines should even be avoided with low-dose and/or intermittent use of immunosuppressant drugs unless the potential benefit outweighs the risk.<sup>12</sup><br><br>Of note, ACIP recommendations acknowledge that the risk of clinically significant immunosuppression is likely dose- and drug-dependent.<sup>12</sup> Consistent with this factor, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with hydroxychloroquine, leflunomide, or methotrexate.<sup>13</sup> Similarly, the ACIP recommendations on the prevention of Herpes Zoster state that therapy with low-doses of methotrexate (0.4 mg/kg/week or less), azathioprine (3.0 mg/kg/day or less), or 6-mercaptopurine (1.5 mg/kg/day or less) are not sufficiently immunosuppressive to create safety concerns and are not contraindications for administration of the zoster vaccine.<sup>14</sup> Systemic corticosteroids also appear subject to dose- and duration-dependency regarding their immunosuppressant effects.<sup>12</sup> With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J, “Methotrexate and Smallpox Vaccination,” <i>Lancet</i>, 1968, ii:1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, and Glatstein HR, “Vaccination of a Patient Receiving Immunosuppressive Therapy for Lymphosarcoma,” <i>JAMA</i>, 1966, 198:737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW, “Routine Immunization of the Immunocompromised Child,” <i>Adv Pediatr Infect Dis</i>, 1987, 2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, et al, “Vaccine-Associated Poliomyelitis in a Child with Sex-Linked Agammaglobulinemia,” <i>J Pediatr</i>, 1977, 91:408-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV, “Poliomyelitis in Hypogammaglobulinemics,” <i>J Infect Dis</i>, 1973, 128:802-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, et al, “Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child,” <i>N Engl J Med</i>, 1977, 297:241-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. CDC, “Disseminated Mycobacterium bovis Infection from BCG Vaccination of a Patient with Acquired Immunodeficiency Syndrome,” <i>MMWR</i>, 1985, 34:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, et al, “Disseminated BCG in HIV Infection,” <i>Arch Dis Child</i>, 1988, 63:1268-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, et al, “Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease,” <i>N Engl J Med</i>, 1987, 316:673-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. CDC, “Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993,” <i>MMWR</i>, 1996, 45:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. Kroger AT, Atkinson WL, Marcuse EK, et al, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR</i>, 2006, 55(RR-15):1-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136024\">[PubMed 17136024]</a></p>\n<p>13. Saag KG, Teng GG, Patkar NM, et al, “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 2008, 59(6):762-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512708\">[PubMed 18512708]</a></p>\n<p>14. Harpaz R, Ortega-Sanchez IR, Seward JF, et al, “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2008, 57(RR-5):1-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528318\">[PubMed 18528318]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5649":"<p><b>Title</b> Trabectedin / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor CPK and for any signs/symptoms of muscle pains or weakness in all patients receiving trabectedin and an HMG-CoA reductase inhibitor (statin). Follow trabectedin monograph recommendations for CPK monitoring closely. Caution patients about the potentially increased risk for muscle toxicity and advise them to immediately report any muscle pains or weakness.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> The trabectedin Canadian product monograph cautions that concurrent use of trabectedin with other agents that can cause rhabdomyolysis, such as the HMG-CoA reductase inhibitors (“statins”), may increase the overall risk for rhabdomyolysis.<sup>1</sup> Rhabdomyolysis, sometimes fatal, has been reported with trabectedin use in the absence of concurrent statin therapy.<sup>1,2,3,4,5,6</sup> According to trabectedin labeling, rhabdomyolysis has been reported in 1.1% or fewer patients, and approximately 4% to 6% of patients treated with trabectedin experienced a grade 3/4 increase in CPK.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yondelis (trabectedin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc.; July 2014.</p>\n<p>2. Yondelis (trabectedin) [prescribing information]. Horsham, PA: Janssen Products, LP; October 2015.</p>\n<p>3. Brain EG. Safety and efficacy of ET-743: the French experience. <i>Anticancer Drugs</i>. 2002;13 Suppl 1:S11-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12173489\">[PubMed 12173489]</a></p>\n<p>4. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. <i>Clin Cancer Res</i>. 2001;7(2):231-242. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11234874\">[PubMed 11234874]</a></p>\n<p>5. Skorupa A, Beldner M, Kraft A, et al. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. <i>Cancer Biol Ther</i>. 2007;6(7):1015-1017. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17611408\">[PubMed 17611408]</a></p>\n<p>6. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. <i>J Clin Oncol</i>. 2004;22(5):890-899. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14990645\">[PubMed 14990645]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5650":"<p><b>Title</b> Trabectedin / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling specifically recommends avoiding this combination, but US labeling does not include such a specific warning.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the hepatotoxic effect of Trabectedin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of alcohol should be avoided in patients being treated with trabectedin. This warning is specifically included in the Canadian product monograph but not in the U.S. prescribing information.</p> \n<p><b>Discussion</b> The trabectedin Canadian product monograph recommends avoiding concurrent use of alcohol due to a possible increased risk for hepatotoxicity.<sup>1</sup> According to the product monograph, reversible acute increases in hepatic transaminases were reported in most patients. Of patients receiving trabectedin 1.5 mg/m<sup>2</sup> infused over 24 hours every 3 weeks, 17% to 39% experienced grade 3/4 elevations in AST/ALT.<sup>1,2</sup> Of patients receiving trabectedin 0.58 mg/m<sup>2</sup> infused over 3 hours every week for 3 weeks, 5% to 9% experienced grade 3/4 elevations in AST/ALT.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yondelis (trabectedin) [product monograph]. Toronto, Ontario, Candada: Janssen Inc.; July 2014.</p>\n<p>2. Yondelis (trabectedin) [prescribing information]. Horsham, PA: Janssen Products, LP; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5660":"<p><b>Title</b> VinCRIStine / Teniposide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teniposide may enhance the neurotoxic effect of VinCRIStine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for signs and symptoms of neuropathy and/or neurotoxicity, and caution patients to promptly report any signs or symptoms of neuropathy/neurotoxicity. Patients with a pre-existing neuopathy or history of neuropathies may be at greater risk. When possible, consider alternative treatments, particularly in high-risk patients. Potential benefit of treatment should outweigh the risks.</p> \n<p><b>Discussion</b> Teniposide prescribing information cautions that concurrent use of teniposide and vincristine may be associated with an increased risk of neurotoxicity, possibly including severe neuropathy.<sup>1</sup> Several clinical studies have documented a particularly high occurrence of neurotoxicity when vincristine is used with teniposide.<sup>2,3,4,5</sup> Although vincristine use has been independently associated with relatively high rates of neurotoxicity, neurotoxicity has not been frequently reported with teniposide use.<sup>1,2</sup> However, a randomized study of 164 subjects found that teniposide was free from neurotoxicity when used without vincristine, but moderate to severe neurotoxicity occurred in almost half the patients treated with teniposide and vincristine.<sup>2</sup> A follow-up study looking at additive therapeutic effects of vincristine and teniposide revealed a statistically and clinically significant increase in neurotoxicity when these agents were combined, without a significant increase in treatment efficacy.<sup>3</sup> Grade 2 and 3 neurotoxicity occurred in 20% of patients receiving both vincristine and teniposide, versus 8% of patients receiving only vincristine and 0% of patients receiving only teniposide.<sup>3</sup> A small study of 9 patients with diffuse cell lymphoma directly investigated the neurotoxic potential of vincristine in combination with teniposide.<sup>4</sup> Neurotoxicity was most commonly reported as symmetrical paresthesia with little or no objective sensory deficit, and occurred in 8 patients (89%). In 4 patients there was a more severe sudden onset of weakness, with patchy asymmetrical motor loss. Deep tendon reflexes were absent in the legs and severely diminished in the arms.<sup>4</sup> In a later study, teniposide in combination with vincristine, cisplatin, and cyclophosphamide was administered to 11 patients with adrenocortical cancer. Peripheral neuropathy occurred in 8 of the 10 patients and 24 of the 60 chemotherapy cycles included in the final analysis; one patient required a 50% reduction in vincristine dose for one cycle and six patients required withdrawal of vincristine in a total of 18 cycles.<sup>5</sup> In contrast to these studies, one study of 56 children whose acute lymphocytic leukemia was treated with combination vincristine and teniposide did not indicate abnormally high rates of neurotoxicity.<sup>6</sup><br><br>The mechanism by which teniposide increases the neurotoxic potential of vincristine is unclear. Teniposide alone does not appear to cause neurotoxicity, nor is it thought to directly interact with the mechanism by which vincristine causes neurotoxicity (inhibition of tubulin dimer polymerization into microtubules involved in axoplasmic transport).<sup>7</sup> It has been postulated that prior or simultaneous administration of teniposide may increase the tubulin’s affinity for vincristine, or make the tubulin more sensitive to the depolymerizing effect of vincristine.<sup>4</sup> Cytochrome P450 (CYP) involvement may play a role in the increased incidence of neurotoxicity seen when vincristine is combined with teniposide. Increased incidence of neurotoxocity has been noted in patients with poor expression of CYP3A5.<sup>8</sup> It has been established that teniposide is metabolized primarily by CYP3A4, but also CYP3A5 to a lesser extent, creating at least a potential for competitive inhibition.<sup>9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vumon (teniposide). Princeton, NJ: Bristol-Myers Squibb Company, December 2010.</p>\n<p>2. Anonymous, “Comparison of the Use of Teniposide and Vincristine in Combination Chemotherapy for Non-Hodgkin’s Lymphoma. The Australian and New Zealand Lymphoma Co-operative Chemotherapy Study Group”, <i>Cancer Treat Rep</i>, 1982, 66(1):49-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7053265\">[PubMed 7053265]</a></p>\n<p>3. Anonymous, “Investigation of the Additive Potential of Teniposide and Vincristine in Non-Hodgkin's Lymphoma. The Australian and New Zealand Lymphoma Co-operative Chemotherapy Study Group,” <i>Cancer Treat Rep</i>, 1986, 70(8): 985-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2873890\">[PubMed 2873890]</a></p>\n<p>4. Griffiths JD, Stark RJ, Ding JC, et al, “Vincristine Neurotoxicity Enhanced in Combination Chemotherapy Including Both Teniposide and Vincristine”, <i>Cancer Treat Rep.</i>, 1986, 70(4):519-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3009012\">[PubMed 3009012]</a></p>\n<p>5. Khan TS, Sundin A, Juhlin C, et al, “Vincristine, Cisplatin, Teniposide, and Cyclophosphamide Combination in the Treatment of Recurrent or Metastatic Adrenocortical Cancer,” <i>Med Oncol</i>, 2004, 21(2):167-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15299189\">[PubMed 15299189]</a></p>\n<p>6. Rivera G, Bowman WP, Murphy SB, et al, “VM-26 with Predisone and Vincristine for Treatment of Refractory Acute Lymphoblastic Leukemia,” <i>Med Pediatr Oncol</i>, 1982, 10(5):439-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6958957\">[PubMed 6958957]</a></p>\n<p>7. Owellen RJ, Hartke CA, Dickerson RM, et al, “Inhibition of Tubulin-Microtubule Polymerization by Drugs of the Vinca Alkaloid Class,” <i>Cancer Res</i>, 1976, 36(4):1499-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1260766\">[PubMed 1260766]</a></p>\n<p>8. Blanco JG, Harrison PL, Evans WE, et al, “Human Cytochrome P450 Maximal Activities in Pediatric Versus Adult Liver,” <i>Drug Metab Dispos</i>, 2000, 28(4):379-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10725303\">[PubMed 10725303]</a></p>\n<p>9. Egbelakin A, Ferguson MJ, Macgill EA, et al, “Increased Risk of Vincristine Neurotoxicity Associated with Low CYP3A5 Expression Genotype in Children with Acute Lymphoblastic Leukemia,” <i>Pediatr Blood Cancer</i>, 2011, 56(3): 361-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21072834\">[PubMed 21072834]</a></p>\n<p>10. Relling MV, Nemec J, Schuetz EG, et al, “O-demethylation of Epipodophyllotoxins is Catalyzed by Human Cytochrome P450 3A4,” <i>Mol Pharmacol</i>, 1994, 45(2): 352-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8114683\">[PubMed 8114683]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5661":"<p><b>Title</b> PredniSONE / Tesamorelin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tesamorelin may decrease serum concentrations of the active metabolite(s) of PredniSONE. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving glucocorticoid replacement therapy with prednisone may required increased maintenance or stress doses when used with tesamorelin. Monitor patients closely for reduced effectiveness of prednisone treatment.</p> \n<p><b>Discussion</b> Tesamorelin prescribing information cautions that use of tesamorelin, which stimulates growth hormone-releasing factor receptors, may indirectly inhibit 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD1) via its effect on growth hormone release, creating a potential for an interaction with glucocorticoids such as prednisone.<sup>1</sup> At clinically relevant doses, human growth hormone (GH) has been shown to inhibit the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD1).<sup>2,3,4,5</sup> This enzyme is required for the bioactivation of prednisone and cortisone. Reduction of the keto moiety at the 11 position of these steroids by 11BHSD results in the formation of the active 11-hydroxy compounds prednisolone and cortisol, respectively. Since all of the other systemic corticosteroids have a parent structure already possessing the 11-hydroxy group, bioactivation is unecessary and these compounds are active at glucocorticoid receptors without enzymatic conversion. <br><br>Whereas the inhibition of 11BHSD by growth hormone has been well established, only a limited number of studies have demonstrated specific GH-mediated inhibition of the pharmacological effects of exogenously administered cortisone<sup>6,7</sup> and prednisone.<sup>8</sup> Nevertheless, it is prudent to carefully monitor the patient for reduced corticosteroid efficacy in this setting.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Egrifta (tesamorelin). Rockland, MA: EMD Serono, Inc., 11/2010.</p>\n<p>2. Paulsen SK, Pedersen SB, Jorgensen JO, et al, “Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11Beta-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue,” <i>J Clin Endocrinol Metab</i>, 2006, 91(3):1093-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368752\">[PubMed 16368752]</a></p>\n<p>3. Tomlinson JW, Crabtree N, Clark PM, et al, “Low-Dose Growth Hormone Inhibits 11 Beta-Hydroxysteroid Dehydrogenase Type 1 But Has No Effect Upon Fat Mass in Patients with Simple Obesity,” <i>J Clin Endocrinol Metab</i>, 2003, 88(5):2113-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12727963\">[PubMed 12727963]</a></p>\n<p>4. Walker EA, Stewart PM, “11Beta-Hydroxysteroid Dehydrogenase: Unexpected Connections,” <i>Trends Endocrinol Metab</i>, 2003, 14(7):334-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12946876\">[PubMed 12946876]</a></p>\n<p>5. Stewart PM, Toogood AA, Tomlinson JW, “Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle,” <i>Horm Res</i>, 2001, 56 Suppl 1:1-6. </p>\n<p>6. Blomgren J, Ekman B, Andersson PO, et al, “Non-Physiological Levels of Circulating Cortisol in Growth Hormone-Treated Hypopituitary Adults After Conventional Cortisone Substitution,” <i>Scand J Clin Lab Invest</i>, 2004, 64(2):132-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15115251\">[PubMed 15115251]</a></p>\n<p>7. Beentjes JA, Kerstens MN, Dullaart RP, “Effects of Growth Hormone Replacement on Cortisol Metabolism in Hypopituitary Patients Treated with Cortisone Acetate,” <i>Scand J Clin Lab Invest</i>, 2001, 61(4):277-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11465341\">[PubMed 11465341]</a></p>\n<p>8. Horber FF, Haymond MW, “Human Growth Hormone Prevents the Protein Catabolic Side Effects of Prednisone in Humans,” <i>J Clin Invest</i>, 1990, 86(1):265-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2195062\">[PubMed 2195062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5662":"<p><b>Title</b> Cortisone / Tesamorelin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tesamorelin may decrease serum concentrations of the active metabolite(s) of Cortisone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving glucocorticoid replacement therapy with cortisone may required increased maintenance or stress doses when used with tesamorelin. Monitor patients closely for reduced effectiveness of cortisone treatment.</p> \n<p><b>Discussion</b> Tesamorelin prescribing information cautions that use of tesamorelin, which stimulates growth hormone-releasing factor receptors, may indirectly inhibit 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD1) via its effect on growth hormone release, creating a potential for an interaction with glucocorticoids such as cortisone.<sup>1</sup> At clinically relevant doses, human growth hormone (GH) has been shown to inhibit 11BHSD1.<sup>2,3,4,5</sup> This enzyme is required for the bioactivation of prednisone and cortisone. Reduction of the keto moiety at the 11 position of these steroids by 11BHSD results in the formation of the active 11-hydroxy compounds prednisolone and cortisol, respectively. Since all of the other systemic corticosteroids have a parent structure already possessing the 11-hydroxy group, bioactivation is unecessary and these compounds are active at glucocorticoid receptors without enzymatic conversion. <br><br>Whereas the inhibition of 11BHSD by growth hormone has been well established, only a limited number of studies have demonstrated specific GH-mediated inhibition of the pharmacological effects of exogenously administered cortisone<sup>6,7</sup> and prednisone.<sup>8</sup> One comparative study evaluated serum cortisol levels as a function of exogenously administered hydrocortisone or cortisone in 10 hypopituitary patients receiving GH supplementation.<sup>9</sup> While further confirming GH-mediated inhibition of 11BHSD (via hydroxyl/oxo cortisol metabolite ratios), this study also demonstrated significant reductions (after initiation of GH therapy) in mean serum cortisol in cortisone-treated patients (-18.7%) and hydrocortisone-treated patients (-10.9%). While it is unclear from this observation why circulating corticosteroid levels were lower after administering an exogenously bioactive steroid (hydrocortisone), it does provide further support for the potential benefit of employing corticosteroid therapy which does not require enzymatic activation in the setting of GH treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Egrifta (tesamorelin). Rockland, MA: EMD Serono, Inc., 11/2010.</p>\n<p>2. Paulsen SK, Pedersen SB, Jorgensen JO, et al, “Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11Beta-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue,” <i>J Clin Endocrinol Metab</i>, 2006, 91(3):1093-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368752\">[PubMed 16368752]</a></p>\n<p>3. Tomlinson JW, Crabtree N, Clark PM, et al, “Low-Dose Growth Hormone Inhibits 11 Beta-Hydroxysteroid Dehydrogenase Type 1 But Has No Effect Upon Fat Mass in Patients with Simple Obesity,” <i>J Clin Endocrinol Metab</i>, 2003, 88(5):2113-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12727963\">[PubMed 12727963]</a></p>\n<p>4. Walker EA, Stewart PM, “11Beta-Hydroxysteroid Dehydrogenase: Unexpected Connections,” <i>Trends Endocrinol Metab</i>, 2003, 14(7):334-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12946876\">[PubMed 12946876]</a></p>\n<p>5. Stewart PM, Toogood AA, Tomlinson JW, “Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle,” <i>Horm Res</i>, 2001, 56 Suppl 1:1-6. </p>\n<p>6. Blomgren J, Ekman B, Andersson PO, et al, “Non-Physiological Levels of Circulating Cortisol in Growth Hormone-Treated Hypopituitary Adults After Conventional Cortisone Substitution,” <i>Scand J Clin Lab Invest</i>, 2004, 64(2):132-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15115251\">[PubMed 15115251]</a></p>\n<p>7. Beentjes JA, Kerstens MN, Dullaart RP, “Effects of Growth Hormone Replacement on Cortisol Metabolism in Hypopituitary Patients Treated with Cortisone Acetate,” <i>Scand J Clin Lab Invest</i>, 2001, 61(4):277-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11465341\">[PubMed 11465341]</a></p>\n<p>8. Horber FF, Haymond MW, “Human Growth Hormone Prevents the Protein Catabolic Side Effects of Prednisone in Humans,” <i>J Clin Invest</i>, 1990, 86(1):265-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2195062\">[PubMed 2195062]</a></p>\n<p>9. Swords FM, Carroll PV, Kisalu J et al, “The Effects of Growth Hormone Deficiency and Replacement on Glucocorticoid Exposure in Hypopituitary Patients on Cortisone Acetate and Hydrocortisone Replacement,” <i>Clin Endocrinol</i>, 2003, 59:613-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616886\">[PubMed 14616886]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5663":"<p><b>Title</b> Lurasidone / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Dosing recommendations may differ depending on international labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Lurasidone U.S. labeling recommends reducing the lurasidone dose by half when used together with a moderate CYP3A4 inhibitor. Some non-U.S. labeling recommends initiating lurasidone at a dose of 20 mg/day and limiting lurasidone to 40 mg/day with concomitant use of moderate CYP3A4 inhibitors. Both U.S. and non-U.S. labeling recommend avoiding concurrent use of grapefruit products, which are moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem*, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Coadministration of diltiazem (240 mg/day) increased lurasidone maximum concentration and AUC by approximately 2-fold each, respectively.<sup>1,2</sup> The likely primary mechanism of this interaction is diltiazem inhibition of CYP3A4-mediated lurasidone metabolism.<br><br>Lurasidone U.S. prescribing information recommends reducing the lurasidone dose by half when used together with a moderate CYP3A4 inhibitor.<sup>1</sup> The lurasidone Canadian product monograph recommends initiating lurasidone at a dose of 20 mg/day and limiting lurasidone to 40 mg/day with concomitant use of moderate CYP3A4 inhibitors.<sup>3</sup> Both U.S. and non-U.S. labeling recommend avoiding concurrent use of grapefruit products, which are moderate CYP3A4 inhibitors.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; July 2013.</p>\n<p>2. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. <i>Drug Metabol Drug Interact</i>. 2014;29(3):191-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24825095\">[PubMed 24825095]</a></p>\n<p>3. Latuda (lurasidone) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc.; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5664":"<p><b>Title</b> Lurasidone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of lurasidone in patients receiving strong CYP3A4 inhibitors. Lurasidone US prescribing information specifically lists this as a contraindication.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, coadministration of ketoconazole (400 mg/day for 5 days) increased the single-dose lurasidone (10 mg) maximum concentration and AUC by 6.9 and 9 fold, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated lurasidone metabolism. Lurasidone prescribing information lists coadministration with any strong CYP3A4 inhibitor as contraindicated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Latuda</i> (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; September 2013.</p>\n<p>2. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. <i>Drug Metabol Drug Interact</i>. 2014;29(3):191-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24825095\">[PubMed 24825095]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5665":"<p><b>Title</b> Lurasidone / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of lurasidone in patients receiving strong CYP3A4 inducers. Lurasidone US prescribing information specifically lists this as a contraindication.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, the strong CYP3A4 inducer rifampin (600 mg daily x 8 days) decreased the lurasidone (40 mg single dose) AUC and maximum serum concentration approximately 81% and 85%, respectively.<sup>1,2</sup> The likely primary mechanism of this interaction is rifampin induction of CYP3A4 mediated lurasidone metabolism. Lurasidone prescribing information lists coadministration with any strong CYP3A4 inducer as contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; January 2017.</p>\n<p>2. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. <i>Drug Metabol Drug Interact</i>. 2014;29(3):191-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24825095\">[PubMed 24825095]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5666":"<p><b>Title</b> Simvastatin / Green Tea</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Green Tea may increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased adverse effects of simvastatin in patients who regularly consume green tea, particularly in large quantities.</p> \n<p><b>Discussion</b> A single case report describes a 61 year old man who experienced leg cramping (without creatine phosphokinase elevation) during trials of simvastatin, atorvastatin, and rosuvastatin (each 10 mg daily) while consuming an average of 3 cups of green tea daily.<sup>1</sup> Kinetic analyses demonstrated a roughly twofold greater AUC of simvastatin lactone when the patient was consuming green tea, compared to a control period without green tea. Upon discontinuation of green tea, the patient tolerated simvastatin 10 mg.<br><br>The mechanism of this interaction is unknown. The authors of the case report propose green tea inhibition of CYP3A4 as a possible mechanism, but clinical and in vitro data do not generally support green tea constituents as clinically significant inhibitors of CYP3A4.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Werba JP, Giroli M, Cavalca V, et al, “The Effect of Green Tea on Simvastatin Tolerability,” <i>Ann Intern Med</i>, 2008, 149(4):286-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18711168\">[PubMed 18711168]</a></p>\n<p>2. Donovan JL, Chavin KD, Devane CL, et al, “Green Tea (Camellia Sinensis) Extract Does Not Alter Cytochrome P450 3A4 or 2D6 Activity in Healthy Volunteers,” <i>Drug Metab Dispos</i>, 2004, 32(9):906-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15319329\">[PubMed 15319329]</a></p>\n<p>3. Chow HH, Hakim IA, Vining DR, et al, “Effects of Repeated Green Tea Catechin Administration on Human Cytochrome P450 Activity,” <i>Cancer Epidemiol Biomarkers Prev</i>, 2006, 15(12):2473-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17164372\">[PubMed 17164372]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5667":"<p><b>Title</b> Folic Acid / Green Tea</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Green Tea may decrease the serum concentration of Folic Acid. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Folate exposure may be optimized by avoiding regular, simultaneous ingestion of green tea with folic acid supplements. The clinical significance of the interaction between these entities has not been established.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, simultaneous ingestion of green tea (0.3 g extract in 250 mL water) with folic acid decreased maximum concentration and AUC of folate by 39.2% and a 26.6%, respectively, using a 0.4 mg oral folic acid dose and 27.4% and 39.9%, respectively, using a 5 mg oral folic acid dose.<sup>1</sup><br><br>The mechanism and clinical significance of this interaction are unknown. Green tea inhibits folate uptake in Caco-2 cell monolayers in vitro, suggesting that intestinal folate absorption may be inhibited in vivo.<sup>2</sup> The effect of separating administration of green tea and folic acid is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Alemdaroglu NC, Dietz U, Wolffram S, et al, “Influence of Green and Black Tea on Folic Acid Pharmacokinetics in Healthy Volunteers: Potential Risk of Diminished Folic Acid Bioavailability,” <i>Biopharm Drug Dispos</i>, 2008, 29(6):335-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18551467\">[PubMed 18551467]</a></p>\n<p>2. Alemdaroglu NC, Wolffram S, Boissel JP, et al, “Inhibition of Folic Acid Uptake by Catechins and Tea Extracts in Caco-2 Cells,” <i>Planta Med</i>, 2007, 73(1):27-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17117344\">[PubMed 17117344]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5668":"<p><b>Title</b> Filgrastim / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lithium may enhance the therapeutic effect of Filgrastim. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required. Note that concurrent use of lithium may be associated with a faster and/or more extensive neutrophil/CD34+ cell response to filgrastim.</p> \n<p><b>Discussion</b> A 33-year-old woman stabilized on lithium 1200 mg/day, with a serum lithium concentration of 0.85 mmol/L, received recombinant human G-CSF at 10 mg/kg/day following chemotherapy for acute myeloid leukemia and hematopoietic recovery.<sup>1</sup> After four days of treatment, the number of CD34+ cells in her peripheral blood was 4.66 x 10<sup>6</sup>/kg and the percentage of CD34+ cells was 0.43%. As a comparison, in fifteen patients with AML treated with G-CSF alone, mean serum levels of CD34+ cells were notably lower (2.57 x 10<sup>6</sup>/kg) with a percentage that ranged from 0.02 to 0.36%.<sup>1</sup> Similarly, several in vivo (human and animal) and in vitro studies have reported increased neutrophil concentrations, increased proportion of CD34+ cells, and increased the production of endogenous G-CSF.<sup>2,3,4,5,6,7</sup><br><br>Based on reports such as these, filgrastim prescribing information recommends caution when using agents such as lithium, which can increase the release of neutrophils.<sup>8</sup><br><br>The specific mechanism(s) by which lithium augments neutrophil release is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Canales MA, Arrieta R, Hernandez-Garcia C, et al, “A Single Apheresis to Achieve a High Number of Peripheral Blood CD34+ Cells in a Lithium-Treated Patient with Acute Myeloid Leukaemia,” <i>Bone Marrow Transplant</i>, 1999, 23(3):305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10084266\">[PubMed 10084266]</a></p>\n<p>2. Tisman G, Herbert V, Rosenblatt S, “Evidence that Lithium Induces Human Granulocyte Proliferation: Elevated Serum Vitamin B 12 Binding Capacity In Vivo and Granulocyte Colony Proliferation In Vitro,” <i>Br J Haematol</i>, 1973, 24(6):767-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4716059\">[PubMed 4716059]</a></p>\n<p>3. Gallicchio VS, Chen MG, Watts TD, “Specificity of Lithium (Li+) to Enhance the Production of Colony Stimulating Factor (GM-CSF) from Mitogen-Stimulated Lymphocytes In Vitro,” <i>Cell Immunol</i>, 1984, 85(1):58-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6608997\">[PubMed 6608997]</a></p>\n<p>4. Ballin A, Lehman D, Sirota P, et al, “Increased Number of Peripheral Blood CD34+ Cells in Lithium-Treated Patients,” <i>Br J Haematol</i>, 1998, 100(1):219-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9450814\">[PubMed 9450814]</a></p>\n<p>5. Harker WG, Rothstein G, Clarkson D, et al, “Enhancement of Colony-Stimulating Activity Production by Lithium,” <i>Blood</i>, 1977, 49(2):263-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=299818\">[PubMed 299818]</a></p>\n<p>6. Boggs DR, Joyce RA, “The Hematopoietic Effects of Lithium,” <i>Semin Hematol</i>, 1983, 20(2):129-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6348956\">[PubMed 6348956]</a></p>\n<p>7. Focosi D, Azzara A, Kast RE, et al, “Lithium and Hematology: Established and Proposed Uses,” <i>J Leukoc Biol</i>, 2009, 85(1):20-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18809733\">[PubMed 18809733]</a></p>\n<p>8. Prescribing information. Neupogen (filgrastim). Thousand Oaks, CA: Amgen Inc., 03/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5669":"<p><b>Title</b> Fosamprenavir / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Posaconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Posaconazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response to both posaconazole and fosamprenavir closely when this combination is used. Specifically, monitor closely for signs/symptoms of fosamprenavir toxicity as well as breakthrough fungal infections. The only available data regarding this combination are with un-boosted fosamprenavir, so it is important to note that ritonavir-boosted fosamprenavir may interact with posaconazole to an extent different from what is expected with un-boosted fosamprenavir.</p> \n<p><b>Discussion</b> The average posaconazole AUC was reduced by 23% when posaconazole (400 mg twice/day) was given with fosamprenavir (700 mg twice/day) in a randomized, three-way cross-over study of 24 healthy volunteers.<sup>1</sup> The specific mechanism by which fosamprenavir may reduce posaconazole concentrations is uncertain. Fosamprenavir is described as being capable of inhibiting or inducing CYP3A.<sup>2</sup> The extent to which fosamprenavir is capable of inducing UDP-glucuronosyltransferases and/or p-glycoprotein, the primary determinants of posaconazole disposition,<sup>3</sup> is unclear.<br><br>In a separate comparison from the same study, amprenavir AUC and maximum serum concentration (Cmax) were an average of 65% and 36% lower with fosamprenavir (700 mg twice/day) plus posaconazole (400 mg twice/day) versus fosamprenavir/ritonavir (700 mg/100 mg twice/day).<sup>1</sup> This comparison was carried out in order to determine is posaconazole could replace the ritonavir “booster” when treatment with posaconazole is being considered. Though it appears that posaconazole, which is characterized as a potent CYP3A4 inhibitor,<sup>3</sup> does not interact with fosamprenavir as significantly as ritonavir does, the nature of this comparison does not permit a valid evaluation of the extent to which posaconazole impacts fosamprenavir concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruggemann RJ, van Luin M, Colbers EP, et al, “Effect of Posaconazole on the Pharmacokinetics of Fosamprenavir and Vice Versa in Healthy Volunteers,” <i>J Antimicrob Chemother</i>, 2010, 65(10):2188-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20667889\">[PubMed 20667889]</a></p>\n<p>2. Prescribing information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2010.</p>\n<p>3. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering Corporation, 6/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5670":"<p><b>Title</b> Propranolol / Lacidipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lacidipine may enhance the hypotensive effect of Propranolol. Lacidipine may increase the serum concentration of Propranolol. Propranolol may decrease the serum concentration of Lacidipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood pressure response closely when using these drugs in combination.</p> \n<p><b>Discussion</b> Lacidipine AUC and maximum serum concentration (Cmax) were an average of 42% and 38% lower, respectively, when lacidipine (4 mg x1) was administered concurrently with propranolol (160 mg x1) in a study of 12 healthy volunteers.<sup>1</sup> In a separate group of 12 healthy volunteers in the same study, propranolol AUC and Cmax were an average of 26% and 35% higher, respectively, with concurrent lacidipine. Blood pressure reductions were also modestly greater with the combination than with either drug given alone (SBP 6 mmHg lower in both study arms with combination; DBP 4 mmHg lower with propranolol + lacidipine vs. lacidipine alone, but DBP not changed with combination vs. propranolol alone).<br><br>The specific mechanism(s) of these apparent pharmacokinetics interactions is(are) unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hall ST, Harding SM, Hassani H, et al, “The Pharmacokinetic and Pharmacodynamic Interaction between Lacidipine and Propranolol in Healthy Volunteers,” <i>J Cardiovasc Pharmacol</i>, 1991, 18 Suppl 11:S13-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1725444\">[PubMed 1725444]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5671":"<p><b>Title</b> Immunosuppressants / Roflumilast</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exceptions</b> Beclomethasone (Oral Inhalation), Cytarabine (Liposomal), Fluticasone (Oral Inhalation)</p>\n</div> \n<p><b>Discussion</b> The Canadian roflumilast product monograph recommends avoiding concurrent use with any immunosuppressant medications due to the lack of relevant clinical experience with such use.<sup>1</sup> This recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions and were allowed in some roflumilast clinical trials) or short-term systemic corticosteroid use. The U.S. prescribing information does not contain this warning about concurrent use with immunosuppressants.<sup>2</sup><br><br>The specific reason for such concern likely involves the antiinflammatory/immune-altering effects of roflumilast and the potential for additive and/or excessive immunosuppression with concurrent use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p>2. Prescribing information. Daliresp (roflumilast). St. Louis, MO: Forest Pharmaceuticals, Inc., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5673":"<p><b>Title</b> Roflumilast / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase serum concentrations of the active metabolite(s) of Roflumilast. FluvoxaMINE may increase the serum concentration of Roflumilast. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response to roflumilast more closely in patients who are also being treated with fluvoxamine. In particular, watch for signs/symptoms of excessive clinical response and/or toxicity.</p> \n<p><b>Discussion</b> Total PDE4 inhibitory activity (tPDE4i) was increased by an average of 59%, reflecting both an average 155% increase in roflumilast AUC and an average 53% increase in roflumilast N-oxide AUC, when fluvoxamine (50 mg/day) was coadministered with a single dose of oral roflumilast (500 mcg) in a non-randomized crossover study in 14 healthy volunteers.<sup>1,2</sup> This increase in tPDE4i and roflumilast/roflumilast N-oxide exposure is likely related to CYP1A2 (primarily) and 2C19 inhibition by fluvoxamine.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. von Richter O, Huennemeyer A, Herzog R, et al, “Effects of Fluvoxamine on the Pharmacokinetics of Roflumilast and Roflumilast N-oxide,” <i>Clin Pharmacokinet</i>, 2007, 46(7):613-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17596106\">[PubMed 17596106]</a></p>\n<p>2. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5674":"<p><b>Title</b> Roflumilast / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Roflumilast. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast. The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.</p> \n<p><b>Discussion</b> Total PDE4 inhibitory activity (tPDE4i) was decreased by an average of 58%, reflecting both an average 80% decrease in roflumilast AUC and an average 56% decrease in roflumilast N-oxide AUC, when rifampin (600 mg/day) was coadministered with a single dose of oral roflumilast (500 mcg) in a non-randomized crossover study in 16 healthy volunteers.<sup>1,2</sup> This decrease in tPDE4i and roflumilast/roflumilast N-oxide exposure is likely related to rifampin-mediated induction of the CYP3A4 and CYP1A2 enzymes responsible for roflumilast metabolism.<sup>1,2,3</sup> U.S. prescribing information states that concomitant use of roflumilast with rifampin in not recommended.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nassr N, Huennemeyer A, von Richter O, et al, “Effects of Rifampicin on the Pharmacokinetics of Roflumilast and Roflumilast N-oxide in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2009, 68(4):580-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19843061\">[PubMed 19843061]</a></p>\n<p>2. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p>3. Prescribing information. Daliresp (roflumilast). St. Louis, MO: Forest Laboratories, Inc., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5676":"<p><b>Title</b> Roflumilast / Theophylline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Theophylline may increase the serum concentration of Roflumilast. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to the product monograph, the total PDE4 inhibitor (tPDE4i) exposure (i.e., total exposure to roflumilast and its active metabolite, roflumilast N-oxide) increased by an average of 8% when roflumilast and theophylline were given concomitantly.<sup>1</sup> The mechanism of this interaction is not certain, but since both drugs are metabolized to a large extent via CYP1A2, competition for this enzyme may be at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5677":"<p><b>Title</b> Clopidogrel / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to clopidogrel more closely in patients receiving concurrent amiodarone (including patients who have discontinued amiodarone within the past several months). In particular, be alert for potentially reduced clopidogrel effectiveness.</p> \n<p><b>Discussion</b> Amiodarone prescribing information cautions that there are reports of reduced clopidogrel effectiveness (i.e., diminished inhibition of platelet aggregation) when clopidogrel and amiodarone are used concomitantly.<sup>1,2</sup> Of note, this purported interaction is not mentioned in the clopidogrel prescribing information,<sup>3</sup> and no other peer-reviewed reports of this interaction have been found.<br><br>The suggested mechanism of this potential interaction is inhibition of the CYP3A4-mediated activation of clopidogrel by amiodarone.<sup>1,2</sup> It is important to note that clopidogrel activation appears primarily dependent on CYP2C19, though CYP3A, CYP2B6, and CYP1A2 are also involved.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cordarone (amiodarone). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 12/10.</p>\n<p>2. Prescribing information. Pacerone (amiodarone). Minneapolis, MN: Upsher-Smith Laboratories, Inc., 01/2011.</p>\n<p>3. Prescribing information. Plavix (clopidogrel). Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, February 2011.</p>\n<p>4. Hulot JS, Bura A, Villard E, et al, “Cytochrome P450 2C19 Loss-of-Function Polymorphism is a Major Determinant of Clopidogrel Responsiveness in Healthy Subjects,” <i>Blood</i>, 2006, 108(7):2244-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772608\">[PubMed 16772608]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5678":"<p><b>Title</b> Simvastatin / Lacidipine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lacidipine may increase the serum concentration of Simvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Simvastatin AUC was an average of 35% higher when simvastatin (40 mg/day) was given with lacidipine (4 mg/day) for 8 days in a study of 18 healthy volunteers.<sup>1</sup> The average simvastatin maximum serum concentration (Cmax) was 70% higher with concurrent therapy, but the simvastatin half-life was not significantly different.<br><br>The specific mechanism of this interaction is uncertain, but since both simvastatin and lacidipine are CYP3A4 substrates, competitive inhibition of simvastatin metabolism may be at least partially responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ziviani L, Da Ros L, Squassante L, et al, “The Effects of Lacidipine on the Steady/State Plasma Concentrations of Simvastatin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2001, 51(2):147-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11259986\">[PubMed 11259986]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5679":"<p><b>Title</b> Roflumilast / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase serum concentrations of the active metabolite(s) of Roflumilast. Cimetidine may increase the serum concentration of Roflumilast. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to roflumilast more closely in patients who are also being treated with cimetidine. In particular, watch for signs/symptoms of excessive clinical response and/or toxicity.</p> \n<p><b>Discussion</b> According to the roflumilast product monograph, total PDE4 inhibitor (tPDE4i) exposure (i.e., total exposure to roflumilast and its active metabolite, roflumilast N-oxide) increased by an average of 47% when roflumlast was coadministered with cimetidine.<sup>1</sup> This increase in tPDE4i and roflumilast/roflumilast N-oxide exposure is likely related to cimetidine-mediated inhibition of CYP1A2 and CYP3A4, the two enzymes primarily responsible for the metabolism of roflumilast.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5680":"<p><b>Title</b> Roflumilast / Ethinyl Estradiol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ethinyl Estradiol may increase the serum concentration of Roflumilast. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to the product monograph, the total PDE4 inhibitor (tPDE4i) exposure (i.e., total exposure to roflumilast and its active metabolite, roflumilast N-oxide) increased by an average of 17% when roflumilast was administered with concurrent ethinyl estradiol/gestodene.<sup>1</sup><br><br>The likely mechanism for this apparent interaction is inhibition of the CYP1A2 (and/or CYP3A4)-mediated roflumilast metabolism by ethinyl estradiol. In several in vivo and in vitro studies, ethinyl estradiol has been shown to be a moderate inhibitor of CYP1A2 activity.<sup>2,3,4</sup> In contrast, gestodene had only a weak inhibitory effect on CYP1A2 in vitro,<sup>3</sup> and the combination (ethinyl estradiol/gestodene) had only a small effect on the AUC of the CYP3A4 substrate midazolam,<sup>5</sup> suggesting minimal impact on CYP3A4 activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Daxas (roflumilast). Oakville, Ontario, Canada: Nycomed Canada Inc., November 2010.</p>\n<p>2. Granfors MT, Backman JT, Laitila J, et al, “Oral Contraceptives Containing Ethinyl Estradiol and Gestodene Markedly Increase Plasma Concentrations and Effects of Tizanidine by Inhibiting Cytochrome P450 1A2,” <i>Clin Pharmacol Ther</i>, 2005, 78(4):400-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198659\">[PubMed 16198659]</a></p>\n<p>3. Karjalainen MJ, Neuvonen PJ, Backman JT, “In Vitro Inhibition of CYP1A2 by Model Inhibitors, Anti-Inflammatory Analgesics and Female Sex Steroids: Predictability of In Vivo Interactions,” <i>Basic Clin Pharmacol Toxicol</i>, 2008, 103(2):157-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18816299\">[PubMed 18816299]</a></p>\n<p>4. Shelepova T, Nafziger AN, Victory J, et al, “Effect of a Triphasic Oral Contraceptive on Drug-Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail,” <i>J Clin Pharmacol</i>, 2005, 45(12):1413-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16291717\">[PubMed 16291717]</a></p>\n<p>5. Palovaara S, Kivisto KT, Tapanainen P, et al, “Effect of an Oral Contraceptive Preparation Containing Ethinylestradiol and Gestodene on CYP3A4 Activity as Measured by Midazolam 1'-Hydroxylation,” <i>Br J Clin Pharmacol</i>, 2000, 50(4):333-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11012556\">[PubMed 11012556]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5691":"<p><b>Title</b> Bezafibrate / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Bezafibrate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs).</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Bezafibrate product monograph states that concomitant use of monoamine oxidase inhibitors (MAOIs) with hepatotoxic potential should be avoided.<sup>1</sup> Varying degrees of hepatotoxicity (including minor and/or rare reports) are mentioned in the labeling of each MAOI available in Canada.<sup>2,3,4,5,6</sup> Bezafibrate has been associated with hepatic dysfunction and though not specifically defined in the labeling, this recommendation may be based on the potential for additive hepatotoxic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Bezafibrate (bezalip). Mississauga, Ontario: McKesson Logistics Solutions, May 2008.</p>\n<p>2. Product monograph. Apo-Moclobemide (moclobemide). Weston, Ontario: Apotex Inc., March 2009.</p>\n<p>3. Product monograph. Mylan-Selegiline. (selegiline). Etobicoke, Ontario: Mylan Pharmaceuticals ULC, July 2009.</p>\n<p>4. Product monograph. Azilect (rasagiline). Toronto, Ontario:Teva Canada Limited, June 2010.</p>\n<p>5. Product monograph. Parnate (tranylcypromine). Mississauga, Ontario: GlaxoSmithKline Inc., May 2010. </p>\n<p>6. Product monograph. Nardil (phenelzine). Westmount, Quebec: Erfa Canada Inc., July 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5692":"<p><b>Title</b> Gefitinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Gefitinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of proton pump inhibitors (PPIs) with gefitinib when possible. If this combination is required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI, and closely monitor clinical response to gefitinib.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Concurrent use of ranitidine and sodium bicarbonate (to achieve and maintain gastric pH above pH 5.0) was associated with an average 44% decrease in gefitinib AUC.<sup>1,2</sup> Gefitinib labeling cautions that concurrent use of drugs that cause sustained elevations in gastric pH (including proton pump inhibitors) may decrease gefitinib plasma concentrations, potentially reducing clinical efficacy.<sup>1,2</sup><br><br>The mechanism for this possible interaction is not certain, but gefitinib aqueous solubility has been shown to decline with increases in gastric pH, particularly as pH increases between pH 4.0 and pH 6.0.<sup>1,2</sup> This could decrease the extent of gefitinib absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2015.</p>\n<p>2. Iressa (gefitinib) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc.; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5693":"<p><b>Title</b> Amiodarone / Azithromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Azithromycin (Systemic) may enhance the QTc-prolonging effect of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided. Concomitant use is expected to substantially increase the risk for serious toxicities, including the development of torsades de pointes (TdP) or other significant ventricular tachyarrhythmias. Patients with other risk factors present (e.g., older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations), would be at an even higher risk for these potentially life-threatening toxicities.</p> \n<p><b>Discussion</b> A single case report documents the occurrence of QT interval prolongation and dispersion upon initiation of azithromycin therapy in a patient on long-term, stable amiodarone therapy.<sup>1</sup> In this case report, a 68-year-old woman on year-long amiodarone therapy (200 mg/day) began azithromycin (500 mg x1 dose, then 250 mg/day x4) for pneumonia. She presented with normal thyroid, liver function, serum electrolytes, sinus rhythm, heart rate, and QTc interval at baseline. Three days after initiating azithromycin (no other medication or dosage changes) she presented with marked bradycardia and significant QTc prolongation (660 ms), which resolved after discontinuation of the antibiotic.<br><br>The mechanism of such an interaction is currently uncertain. There is no evidence to suggest that azithromycin impairs the metabolism of amiodarone, as azithromycin's inability to inhibit CYP3A4 activity is well-documented.<sup>2,3,4</sup> Several case reports<sup>5,6,7,8,9,10,11,12</sup> and two studies<sup>13,14</sup> suggest that azithromycin itself may predispose to QTc prolongation or rhythm disturbances, and as such, azithromycin is considered a “moderate risk QTc-prolonging agent” in this database. However, it should be noted that confounding variables in some of these reports raise at least some questions about the true relationship between azithromycin use and QTc prolongation. In two cases, patients presented with underlying dilated cardiomyopathies,<sup>5,6</sup> one with possible alcohol-related hepatic impairment as well (which could have contributed to elevated azithromycin levels). A third case involved an infant with a toxic azithromycin overdose, leading to life-threatening bradycardia.<sup>7</sup> A fourth report suggested azithromycin was related to the occurrence of polymorphic ventricular tachycardia, but with no evidence of QTc prolongation.<sup>8</sup> Interestingly, the patient in this latter case also had a history of hypothyroidism, which can be a risk factor for arrythmogenesis.<br><br>A large cohort study of 347,795 patients who received azithromycin, approximately 1.8 million patients who received another antibacterial, and approximately 1.4 million patients who did not receive antibacterials reported an increased risk of cardiovascular death among patients treated with azithromycin (hazard ratio = 2.9 vs. those not receiving any antibacterial and 2.4 vs. those receiving amoxicillin).<sup>13</sup> The risk was highest among those with known cardiovascular disease. Of importance, the outcomes in this study were not specific to QT-related changes, and though pro-arrhythmic effects may have contributed to the observed outcomes, data to support any such association are not available. A prospective trial in 47 patients treated for erythema migrans noted that azithromycin (600 mg/day x 5 days) was associated with a modest, but statistically insignificant prolongation of the QT interval.<sup>14</sup> In these patients, the magnitude of values exceeding the upper limit of normal was similar in pre- and during-treatment exposure. Thus, whether azithromycin is truly associated with a clinically-relevant disruption of cardiac conduction is unknown. Such a phenomenon may only manifest in extreme circumstances, i.e., excessive azithromycin blood levels, and/or in conjunction with serious, underlying cardiovascular co-morbidities.<br><br>Several drugs have been associated with the development of life-threatening ventricular arrhythmias, including most notably the polymorphic ventricular tachyarrhythmia torsades de pointes (TdP). Prolongation of the QT interval on the ECG is currently the best available biomarker to assess the risk for development of TdP or other ventricular tachyarrhythmias. However, QT-prolongation is not a perfect indicator of risk as not all QT-prolonging drugs increase the risk for TdP, there is considerable variability in patient sensitivity to QT prolongation, and the QT interval is difficult to measure accurately and is subject to considerable beat-to-beat variability.<sup>15,16,17,18</sup> Despite the limitations of the QT interval as a biomarker for TdP risk, there is a general association between QT-prolongation and risk for TdP. Among patients with congenital long QT syndrome (LQTS), each 10 msec increase in the rate-corrected QT (QTc) interval is associated with a 5-7% exponential increase in risk for TdP, and a QTc of over 500 msec is associated with a 2- to 3-fold increase in TdP risk.<sup>15</sup> The risk of drug-induced QT prolongation and TdP is thought to be similar to these shown with congenital LQTS. According to an FDA Guidance for Industry regarding QT/QTc assessment, QT interval increases of 5 msec or less are generally considered to indicate no increase in TdP risk, while increases of 5 to less than 20 msec indicate a possible increase in risk and increases of 20 msec or more indicate a substantially increased risk.<sup>16</sup><br><br>Many risk factors that may increase a patient's risk for TdP development associated with the use of QT-prolonging drugs have been identified. Factors known to increase patients' risk include female sex, age over 65 years, bradycardia, hypokalemia, hypomagnesemia, underlying heart disease, higher concentrations of one or more QT-prolonging drugs, and genetic predisposition.<sup>15,16,17,18</sup><br><br>Although the risks associated with higher serum concentrations of a QT-prolonging drug have been well characterized (e.g., terfenadine drug interactions leading to its withdrawal from the U.S. market), the specific risks associated with concurrent use of multiple QT-prolonging drugs (apart from a pharmacokinetic interaction) has not been well-described. In one review of 70 patients who experienced QT prolongation with IV haloperidol, 68 (97%) patients had other risk factors for QT prolongation, and concurrent use of another QT-prolonging drug was the most common risk factor identified.<sup>19</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Samarendra P, Kumari S, Evans SJ, et al, “QT Prolongation Associated with Azithromycin/Amiodarone Combination,” <i>Pacing Clin Electrophysiol</i>, 2001, 24(10):1572-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11707055\">[PubMed 11707055]</a></p>\n<p>2. Ito K, Ogihara K, Kanamitsu S, et al, “Prediction of the <i>In Vivo</i> Interaction Between Midazolam and Macrolides Based on <i>In Vitro</i> Studies Using Human Liver Microsomes,” <i>Drug Metab Dispos</i>, 2003, 31(7):945-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814973\">[PubMed 12814973]</a></p>\n<p>3. Yeates RA, Laufen H, Zimmermann T, et al, “Pharmacokinetic and Pharmacodynamic Interaction Study Between Midazolam and the Macrolide Antibiotics, Erythromycin, Clarithromycin, and the Azalide Azithromycin,” <i>Int J Clin Pharmacol Ther</i>, 1997, 35(12):577-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9455717\">[PubMed 9455717]</a></p>\n<p>4. Backman JT, Olkkola KT and Neuvonen PJ, “Azithromycin Does Not Increase Plasma Concentrations of Oral Midazolam,” <i>Int J Clin Pharmacol Ther</i>, 1995, 33(6):356-9.</p>\n<p>5. Russo V, Puzio G and Siniscalchi N, “Azithromycin-Induced QT Prolongation in Elderly Patient,” <i>Acta Biomed</i>, 2006, 77(1):30-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16856707\">[PubMed 16856707]</a></p>\n<p>6. Matsunaga N, Oki Y and Prigollini A, “A Case of QT-Interval Prolongation Precipitated by Azithromycin,” <i>N Z Med J</i>, 2003, 116(1185):U666. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14615808\">[PubMed 14615808]</a></p>\n<p>7. Tilelli JA, Smith KM and Pettignano R, “Life-Threatening Bradyarrhythmia After Massive Azithromycin Overdose,” <i>Pharmacotherapy</i>, 2006, 26(1):147-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16506357\">[PubMed 16506357]</a></p>\n<p>8. Kim MH, Berkowitz C and Trohman RG, “Polymorphic Ventricular Tachycardia with a Normal QT Interval Following Azithromycin,” <i>Pacing Clin Electrophysiol</i>, 2005, 28(11):1221-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359290\">[PubMed 16359290]</a></p>\n<p>9. Winton JC and Twilla JD, “Sudden Cardiac Arrest in a Patient on Chronic Methadone After the Addition of Azithromycin,” <i>Am J Med Sci</i>, 2013, 345(2):160-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23103438\">[PubMed 23103438]</a></p>\n<p>10. Kezerashvili A, Khattak H, Barsky A, et al, “Azithromycin as a Cause of the QT-Interval Prolongation and Torsade de Pointes in the Absence of Other Known Precipitating Factors,” <i>J Interv Card Electrophysiol</i>, 2007, 18(3):243-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17546486\">[PubMed 17546486]</a></p>\n<p>11. Santos N, Oliveira M, Galrinho A, et al, “QT Interval Prolongation and Extreme Bradycardia After a Single Dose of Azithromycin,” <i>Rev Port Cardiol</i>, 2010, 29(10):139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20391905\">[PubMed 20391905]</a></p>\n<p>12. Huang BH, Wu CH, Hsia CP, et al, “Azithromycin-Induced Torsade De Pointes,” <i>Pacing Clin Electrophysiol</i>, 2007, 30(12):1579-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18070319\">[PubMed 18070319]</a></p>\n<p>13. Ray WA, Murray KT, Hall K, et al, “Azithromycin and the Risk of Cardiovascular Death,” <i>N Engl J Med</i>, 2012, 366(20): 1881-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22591294\">[PubMed 22591294]</a></p>\n<p>14. Strle F and Maraspin V, “Is Azithromycin Treatment Associated with Prolongation of the Q-Tc Interval?” <i>Wien Klin Wochenschr</i>, 2002, 114(10-11):396-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12708094\">[PubMed 12708094]</a></p>\n<p>15. Drew BJ, Ackerman MJ, Funk M, et al, “Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement from the American Heart Association and the American College of Cardiology Foundation,” J Am Coll Cardiol, 2010, 55(9):934-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20185054\">[PubMed 20185054]</a></p>\n<p>16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), “Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs,” http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357.pdf?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Clinical Evaluation of QT/QTc&amp;utm_content=5, October 2005.</p>\n<p>17. Kannankeril P, Roden DM, Darbar D, “Drug-Induced Long QT Syndrome,” Pharmacol Rev, 2010, 62(4):760-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21079043\">[PubMed 21079043]</a></p>\n<p>18. Ponte ML, Keller GA, Di Girolamo G, “Mechanisms of Drug Induced QT Interval Prolongation,” Curr Drug Saf, 2010, 5(1):44-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20210718\">[PubMed 20210718]</a></p>\n<p>19. Meyer-Massetti C, Cheng CM, Sharpe BA, et al, “The FDA Extended Warning for Intravenous Haloperidol and Torsades de Pointes: How Should Institutions Respond?” J Hosp Med, 2010, 5(4):E8-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20394022\">[PubMed 20394022]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5694":"<p><b>Title</b> Azithromycin (Systemic) / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nelfinavir may increase the serum concentration of Azithromycin (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased adverse effects of azithromycin (including liver enzyme abnormalities and hearing impairment) if coadministered with nelfinavir.</p> \n<p><b>Discussion</b> The AUC of azithromycin (1200 mg) increased by approximately 112% in 12 healthy volunteers when administered on day 9 of an 11-day regimen of nelfinavir (750 mg every 8 hours).<sup>1,2</sup> The AUC of nelfinavir decreased by approximately 15% on average.<br><br>Neither the mechanism of this pharmacokinetic interaction, nor its clinical implications, are clear. Nelfinavir, a strong p-glycoprotein inhibitor<sup>3</sup>, might inhibit the transport and elimination of azithromycin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Amsden GW, Nafziger AN, Foulds G, et al, “A Study of the Pharmacokinetics of Azithromycin and Nelfinavir When Coadministered in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2000, 40(12 Pt 2):1522-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11185676\">[PubMed 11185676]</a></p>\n<p>2. Prescribing information. Viracept (nelfinavir mesylate). La Jolla, CA: Agouron Pharmaceuticals, Inc, April 2010.</p>\n<p>3. Choo EF, Leake B, Wandel C, et al, “Pharmacological Inhibition of P-glycoprotein Transport Enhances the Distribution of HIV-1 Protease Inhibitors into Brain and Testes,” <i>Drug Metab Dispos</i>, 2000, 28:655-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10820137\">[PubMed 10820137]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5695":"<p><b>Title</b> Vinorelbine / Gefitinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gefitinib may enhance the neutropenic effect of Vinorelbine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients receiving gefitinib with vinorelbine should be diligently monitored due to a possible elevated risk of neutropenia (including severe neutropenia).</p> \n<p><b>Discussion</b> While gefitinib is generally associated with a low incidence of neutropenia when used alone (2.5% of patients in clinical studies cited in Canadian prescribing information), severe neutropenia (Common Toxicity Criteria grade 3 or 4) has been reported in several studies of gefitinib in combination with vinorelbine.<sup>1,2,3,4</sup> This effect resulted in early termination of two clinical studies of the combination.<sup>1</sup><br><br>The mechanism of this interaction is not clear, nor is it clear whether gefitinib might exacerbate the neutropenic effects of any cytotoxic agents other than vinorelbine. In one study, there was no significant change in the AUC of gefitinib or vinorelbine when used in combination.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Iressa (gefitinib). Mississauga, Ontario: AstraZeneca Canada Inc, October 2010.</p>\n<p>2. Pujol JL, Viens P, Rebattu P, et al, “Gefitinib (IRESSA) With Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-Small Cell Lung Cancer Patients,” <i>J Thorac Oncol</i>, 2006, 1(5):417-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17409893\">[PubMed 17409893]</a></p>\n<p>3. Yoshimura M, Nakamura S, Imamura F, et al, “Severe Myelotoxicity in a Combination of Gefitinib and Vinorelbine,” <i>Lung Cancer</i>, 2004, 45(1):121-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15196742\">[PubMed 15196742]</a></p>\n<p>4. Gioulbasanis I, Saridaki Z, Kalykaki A, et al, “Gefitinib in Combination With Gemcitabine and Vinorelbine in Patients With Metastatic Breast Cancer Pre-Treated With Taxane and Anthracycline Chemotherapy: A Phase I/II Trial,” <i>Anticancer Res</i>, 2008, 28(5B):3019-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19031950\">[PubMed 19031950]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5696":"<p><b>Title</b> Gefitinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume at 250 mg dose 7 days after discontinuation of the strong CYP3A4 inducer. Carefully monitor clinical response and development of adverse reactions.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for gefitinib recommends that a 500 mg daily dose of gefitinib dose be considered in patients who are receiving strong CYP3A4 inducers (phenytoin and rifampin are mentioned specifically), in the absence of severe adverse drug reactions.<sup>1</sup> In clinical studies, coadministration of rifampin (600 mg/day orally for 10 days prior to gefitinib) or phenytoin (2.5 mg/kg orally twice daily for 5 days prior to gefitinib) reduced AUC of gefitinib by approximately 47% and 83%, respectively.<sup>1,2,3</sup><br><br>The presumed mechanism of this interaction is induction of CYP3A4-mediated gefitinib metabolism, leading to decreased systemic exposure. In vitro data suggest that gefitinib is metabolized primarily by CYP3A4.<sup>1,4,5</sup> However, the interactions seen with phenytoin and rifampin could be partially attributable to induction of other routes of gefitinib metabolism (e.g., CYP1A2, 2C9).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Iressa (gefitinib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2015.</p>\n<p>2. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. <i>Clin Pharmacokinet</i>. 2005;44(10):1067-1081. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16176119\">[PubMed 16176119]</a></p>\n<p>3. Chhun S, Verstuyft C, Rizzo-Padoin N, et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. <i>Br J Clin Pharmacol</i>. 2009;68(2):226-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19694743\">[PubMed 19694743]</a></p>\n<p>4. McKillop D, McCormick AD, Millar A, Miles GS, Phillips PJ, Hutchison M. Cytochrome P450-dependent metabolism of gefitinib. <i>Xenobiotica</i>. 2005;35(1):39-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15788367\">[PubMed 15788367]</a></p>\n<p>5. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. <i>Clin Cancer Res</i>. 2007;13(12):3731-3737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17575239\">[PubMed 17575239]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5697":"<p><b>Title</b> Methylene Blue / Selective Serotonin Reuptake Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of selective serotonin reuptake inhibitors (SSRIs) for a period of 2 weeks (3 weeks for vortioxetine, 5 weeks for fluoxetine) prior to administration of methylene blue. [Note: Canadian product labeling differs slightly in that it recommends consideration of serotonin reuptake inhibitor discontinuation for 4-5 half lives prior to methylene blue.] In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue the SSRI immediately and monitor closely for signs of CNS toxicity for 2 weeks (3 weeks for vortioxetine, 5 weeks for fluoxetine) after the last SSRI dose, or 24 hours after the last dose of methylene blue, whichever comes first. SSRI treatment may be resumed 24 hours after the last dose of methylene blue.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5698":"<p><b>Title</b> Methylene Blue / Serotonin/Norepinephrine Reuptake Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of serotonin/norepinephrine reuptake inhibitors (SNRIs) for a period of 2 weeks prior to administration of methylene blue. [Note: Canadian product labeling differs slightly in that it recommends consideration of serotonin reuptake inhibitor discontinuation for 4-5 half lives prior to methylene blue.] In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue the SNRI immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last SNRI dose, or 24 hours after the last dose of methylene blue, whichever comes first. SNRI treatment may be resumed 24 hours after the last dose of methylene blue.</p>\n<div>\n <p><b>Serotonin/Norepinephrine Reuptake Inhibitors Interacting Members</b> Desvenlafaxine, DULoxetine, Levomilnacipran, Milnacipran, Venlafaxine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5699":"<p><b>Title</b> Methylene Blue / Mirtazapine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (systemic): This interaction has only been reported with intravenous methylene blue, but could theoretically also occur with large oral doses.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mirtazapine may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, the U.S. Food and Drug Administration recommends discontinuation of mirtazapine for a period of 2 weeks prior to administration of methylene blue. [Note: Canadian product labeling differs slightly in that it recommends consideration of serotonin reuptake inhibitor discontinuation for 4-5 half lives prior to methylene blue.] Similarly, the mirtazapine prescribig information contraindicates initiation of mirtazapine in a patient who is receiving methylene blue. In emergency situations, the availability of alternative agents and interventions should be considered. If the benefit of methylene blue under such circumstances outweighs the risk of serotonin toxicity, discontinue mirtazapine immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last mirtazapine dose, or 24 hours after the last dose of methylene blue, whichever comes first. Mirtazapine treatment may be resumed 24 hours after the last dose of methylene blue.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome in patients receiving methylene blue during treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine),<sup>1,2,3,4,5,6,7,8,9,10,11</sup> tricyclic antidepressants (clomipramine),<sup>12,13</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>11,14,15</sup> and mirtazipine.<sup>11</sup> Methylene blue doses as low as 1 mg/kg (single dose) have been implicated in these cases. In addition, one retrospective chart review identified a number of cases of postoperative neurologic sequelae in patients receiving methylene blue during treatment with serotonin reuptake inhibitors.<sup>16</sup><br><br>In vitro data indicate that methylene blue inhibits monoamine oxidase (MAO), particularly the MAO-A isoform.<sup>17,18</sup> The Canadian product monograph for methylene blue notes that it has chemical structural properties similar to other MAO inhibitors, and contains a boxed warning recommending that prescribers carefully consider discontinuation of serotonin reuptake inhibitors for a period of at least 4-5 half-lives prior to administration of methylene blue.<sup>19</sup> The U.S. Food and Drug Administration issued a Drug Safety Communication in July 2011 regarding this interaction, with more detailed recommendations as described above in Management.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bach KK, Lindsay FW, Berg LS, et al, “Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy,” <i>Anesth Analg</i>, 2004, 99(5):1573-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15502068\">[PubMed 15502068]</a></p>\n<p>2. Khavandi A, Whitaker J and Gonna H, “Serotonin Toxicity Precipitated by Concomitant Use of Citalopram and Methylene Blue,” <i>Med J Aust</i>, 2008, 189(9):534-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18976207\">[PubMed 18976207]</a></p>\n<p>3. Martindale SJ and Stedeford JC, “Neurological Sequelae Following Methylene Blue Injection for Parathyroidectomy,” <i>Anaesthesia</i>, 2003, 58(10):1041-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12969068\">[PubMed 12969068]</a></p>\n<p>4. Mathew S, Linhartova L and Raghuraman G, “Hyperpyrexia and Prolonged Postoperative Disorientation Following Methylene Blue Infusion During Parathyroidectomy,” <i>Anaesthesia</i>, 2006, 61(6):580-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16704594\">[PubMed 16704594]</a></p>\n<p>5. Ng BK, Cameron AJ, Liang R, et al, “Serotonin Syndrome Following Methylene Blue Infusion During Parathyroidectomy: A Case Report and Literature Review,” <i>Can J Anaesth</i>, 2008, 55(1):36-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18166746\">[PubMed 18166746]</a></p>\n<p>6. Schwiebert C, Irving C and Gillman PK, “Small Doses of Methylene Blue, Previously Considered Safe, Can Precipitate Serotonin Toxicity,” <i>Anaesthesia</i>, 2009, 64(8):924. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19604213\">[PubMed 19604213]</a></p>\n<p>7. Shanmugam G, Kent B, Alsaiwadi T, et al, “Serotonin Syndrome Following Cardiac Surgery,” <i>Interact Cardiovasc Thorac Surg</i>, 2008, 7(4):656-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18334520\">[PubMed 18334520]</a></p>\n<p>8. Pollack G, Pollack A, Delfiner J, et al, “Parathyroid Surgery and Methylene Blue: A Review With Guidelines for Safe Intraoperative Use,” <i>Laryngoscope</i>, 2009, 119(10):1941-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19598213\">[PubMed 19598213]</a></p>\n<p>9. Stanford BJ and Stanford SC, “Postoperative Delirium Indicating an Adverse Drug Interaction Involving the Selective Serotonin Reuptake Inhibitor, Paroxetine?” <i>J Psychopharmacol</i>, 1999, 13(3):313-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>10. Stanford SC, Stanford BJ and Gillman PK, “Risk of Severe Serotonin Toxicity Following Co-Administration of Methylene Blue and Serotonin Reuptake Inhibitors: An Update on a Case Report of Post-Operative Delirium,” <i>J Psychopharmacol</i>, 2010, 24(10):1433-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>11. Sweet G and Standiford SB, “Methylene-Blue-Associated Encephalopathy,” <i>J Am Coll Surg</i>, 2007, 204(3):454-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17324781\">[PubMed 17324781]</a></p>\n<p>12. Heritier Barras AC, Walder B, et al, “Serotonin Syndrome Following Methylene Blue Infusion: A Rare Complication of Antidepressant Therapy,” <i>J Neurol Neurosurg Psychiatry</i>, 2010, 81(12):1412-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20547626\">[PubMed 20547626]</a></p>\n<p>13. Khan MA, North AP and Chadwick DR, “Prolonged Postoperative Altered Mental Status After Methylene Blue Infusion During Parathyroidectomy: A Case Report and Review of the Literature,” <i>Ann R Coll Surg Engl</i>, 2007, 89(2):W9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346391\">[PubMed 17346391]</a></p>\n<p>14. Majithia A and Stearns MP, “Methylene Blue Toxicity Following Infusion to Localize Parathyroid Adenoma,” <i>J Laryngol Otol</i>, 2006, 120(2):138-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16359577\">[PubMed 16359577]</a></p>\n<p>15. Rowley M, Riutort K, Shapiro D, et al, “Methylene Blue-Associated Serotonin Syndrome: A 'Green' Encephalopathy After Parathyroidectomy,” <i>Neurocrit Care</i>, 2009, 11(1):88-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19263250\">[PubMed 19263250]</a></p>\n<p>16. Kartha SS, Chacko CE, Bumpous JM, et al, “Toxic Metabolic Encephalopathy After Parathyroidectomy With Methylene Blue Localization,” <i>Otolaryngol Head Neck Surg</i>, 2006, 135(5):765-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17071309\">[PubMed 17071309]</a></p>\n<p>17. Ramsay RR, Dunford C and Gillman PK, “Methylene Blue and Serotonin Toxicity: Inhibition of Monoamine Oxidase A (MAO A) Confirms a Theoretical Prediction,” <i>Br J Pharmacol</i>, 2007, 152(6):946-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17721552\">[PubMed 17721552]</a></p>\n<p>18. Harvey BH, Duvenhage I, Viljoen F, et al, “Role of Monoamine Oxidase, Nitric Oxide Synthase and Regional Brain Monoamines in the Antidepressant-Like Effects of Methylene Blue and Selected Structural Analogues,” <i>Biochem Pharmacol</i>, 2010, 80(10):1580-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20699087\">[PubMed 20699087]</a></p>\n<p>19. Product monograph. Methylene blue. Toronto, ON: Alveda Pharmaceuticals Inc., October 2010.</p>\n<p>20. U.S. Food and Drug Administration, “FDA Drug Safety Communication: Serious CNS Reactions Possible When Methylene Blue is Given to Patients Taking Certain Psychiatric Medications,” http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm, July 2011. Accessed online 7/26/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}